

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/18554 A2

(51) International Patent Classification: C12N 9/00

(21) International Application Number: PCT/US01/26403

(22) International Filing Date: 24 August 2001 (24.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/228,893 30 August 2000 (30.08.2000) US
09/784,340 16 February 2001 (16.02.2001) US(71) Applicant: APPLERA CORPORATION [US/US];
Robert A. MILLMAN, Assistant Secretary, 761 Main
Avenue, Norwalk, CT 06859 (US).(72) Inventors: WEI, Ming-Hui; c/o Celera Genomics, 45
West Gude Drive, Rockville, MD 20850 (US). YE, Jane;
c/o Celera Genomics, 45 West Gude Drive, Rockville,
MD 20850 (US). KETCHUM, Karen A.; c/o Celera Ge-
nomics, 45 West Gude Drive, Rockville, MD 20850 (US).
DI FRANCESCO, Valentina; c/o Celera Genomics, 45West Gude Drive, Rockville, MD 20850 (US). BEASLEY,
Ellen M.; c/o Celera Genomics, 45 West Gude Drive,
Rockville, MD 20850 (US).(74) Agent: CELERA GENOMICS; Robert A. Millman,
Patent Director, 45 West Gude Drive C2-4, Rockville, MD
20850 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

[Continued on next page]

(54) Title: ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN
DRUG-METABOLIZING PROTEINS, AND USES THEREOF

1 CACATATG AGATCACTT GTGAGGAGT TGCATCATG AGGCTGAGT
51 ACTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
181 TCTCTGAG AGATCTGAT GTGAGGAGT TGCATCATG AGGCTGAGT
131 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
201 TATGATGTA CTGAGGCTT TCTGATG TCTTCTCTG TCTGCTG
251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
1951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
2951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
3951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
4951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
5951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
6951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
7951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
8951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9051 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9101 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9151 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9201 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9251 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9301 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9351 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9401 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9451 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9501 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9551 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9601 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9651 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9701 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9751 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9801 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9851 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9901 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
9951 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG
10001 TCTGAGCTT GATATGTTG TCTGATG TCTTCTCTG TCTGCTG

(57) Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the drug-metabolizing enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the drug-metabolizing enzyme peptides, and methods of identifying modulators of the drug-metabolizing enzyme peptides.



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID
MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS,
AND USES THEREOF**

RELATED APPLICATIONS

The present application claims priority to provisional application U.S. Serial No. 60/228,893 filed August 30, 2000 (Atty. Docket CL000763-PROV) and U.S. Serial No. 09/784,340, filed February 16, 2001 (Atty. Docket CL000763).

FIELD OF THE INVENTION

The present invention is in the field of drug-metabolizing proteins that are related to the UDP-glucuronosyltransferase drug-metabolizing enzyme subfamily, recombinant DNA molecules and protein production. The present invention specifically provides novel drug-metabolizing peptides and proteins and nucleic acid molecules encoding such protein molecules, for use in the development of human therapeutics and human therapeutic development.

BACKGROUND OF THE INVENTION

Drug-Metabolizing Proteins

Induction of drug-metabolizing enzymes ("DMEs") is a common biological response to xenobiotics, the mechanisms and consequences of which are important in academic, industrial, and regulatory areas of pharmacology and toxicology.

For most drugs, drug-metabolizing enzymes determine how long and how much of a drug remains in the body. Thus, developers of drugs recognize the importance of characterizing a drug candidate's interaction with these enzymes. For example, polymorphisms of the drug-metabolizing enzyme CYP2D6, a member of the cytochrome p450 ("CYP") superfamily, yield phenotypes of slow or ultra-rapid metabolizers of a wide spectrum of drugs including antidepressants, antipsychotics, beta-blockers, and antiarrhythmics. Such abnormal rates of drug metabolism can lead to drug ineffectiveness or to systemic accumulation and toxicity.

For pharmaceutical scientists developing a candidate drug, it is important know as early as possible in the design phase which enzymes metabolize the drug candidate and the speed with which they do it. Historically, the enzymes on a drug's metabolic pathway were determined through metabolism studies in animals, but this approach has now been largely supplanted by the use of human tissues or cloned drug-metabolizing enzymes to provide insights into the specific role of individual forms of these enzymes. Using these tools, the qualitative and quantitative fate of a drug candidate can be predicted prior to its first administration to humans. As a consequence, the selection and optimization of desirable characteristics of metabolism are possible early in the development process, thus avoiding unanticipated toxicity problems and associated costs subsequent to the drug's clinical investigation. Moreover, the effect of one drug on another's disposition can be inferred.

Known drug-metabolizing enzymes include the cytochrome p450 ("CYP") superfamily, N-acetyl transferases ("NAT"), UDP-glucuronosyl transferases ("UGT"), methyl transferases, alcohol dehydrogenase ("ADH"), aldehyde dehydrogenase ("ALDH"), dihydropyrimidine dehydrogenase ("DPD"), NADPH:quinone oxidoreductase ("NQO" or "DT diaphorase"), catechol O-methyltransferase ("COMT"), glutathione S-transferase ("GST"), histamine methyltransferase ("HMT"), sulfotransferases ("ST"), thiopurine methyltransferase ("TPMT"), and epoxide hydroxylase. Drug-metabolizing enzymes are generally classified into two phases according to their metabolic function. Phase I enzymes catalyze modification of functional groups, and phase II enzymes catalyze conjugation with endogenous substituents. These classifications should not be construed as exclusive nor exhaustive, as other mechanisms of drug metabolism have been discovered. For example, the use of active transport mechanisms been characterized as part of the process of detoxification.

Phase I reactions include catabolic processes such as deamination of aminases, hydrolysis of esters and amides, conjugation reactions with, for example, glycine or sulfate, oxidation by the cytochrome p450 oxidation/reduction enzyme system and degradation in the fatty acid pathway. Hydrolysis reactions occur mainly in the liver and plasma by a variety of non-specific hydrolases and esterases. Both deaminases and amidases, also localized in the liver and serum, carry out a large part of the catabolic process. Reduction reactions occur mainly intracellularly in the endoplasmic reticulum.

Phase II enzymes detoxify toxic substances by catalyzing their conjugation with water-soluble substances, thus increasing toxins' solubility in water and increasing their rate of excretion. Additionally, conjugation reduces the toxins' biological reactivity. Examples of

phase II enzymes include glutathione S-transferases and UDP-glucuronosyl transferases, which catalyze conjugation to glutathione and glucuronic acid, respectively. Transferases perform conjugation reactions mainly in the kidneys and liver.

The liver is the primary site of elimination of most drugs, including psychoactive drugs, and contains a plurality of both phase I and phase II enzymes that oxidize or conjugate drugs, respectively.

Physicians currently prescribe drugs and their dosages based on a population average and fail to take genetic variability into account. The variability between individuals in drug metabolism is usually due to both genetic and environmental factors, in particular, how the drug-metabolizing enzymes are controlled. With certain enzymes, the genetic component predominates and variability is associated with variants of the normal, wild-type enzyme.

Most drug-metabolizing enzymes exhibit clinically relevant genetic polymorphisms. Essentially all of the major human enzymes responsible for modification of functional groups or conjugation with endogenous substituents exhibit common polymorphisms at the genomic level. For example, polymorphisms expressing a non-functioning variant enzyme results in a sub-group of patients in the population who are more prone to the concentration-dependent effects of a drug. This sub-group of patients may show toxic side effects to a dose of drug that is otherwise without side effects in the general population. Recent development in genotyping allows identification of affected individuals. As a result, their atypical metabolism and likely response to a drug metabolized by the affected enzyme can be understood and predicted, thus permitting the physician to adjust the dose of drug they receive to achieve improved therapy.

A similar approach is also becoming important in identifying risk factors associated with the development of various cancers. This is because the enzymes involved in drug metabolism are also responsible for the activation and detoxification of chemical carcinogens. Specifically, the development of neoplasia is regulated by a balance between phase I enzymes, which activate carcinogens, and phase II enzymes, which detoxify them. Accordingly, an individual's susceptibility to cancer often involves the balance between these two processes, which is, in part, genetically determined and can be screened by suitable genotyping tests. Higher induction of phase I enzymes compared to phase II enzymes results in the generation of large amounts of electrophiles and reactive oxygen species and may cause DNA and membrane damage and other adverse effects leading to neoplasia.

Conversely, higher levels of phase II enzyme expression can protect cells from various chemical compounds.

Abnormal activity of drug-metabolizing enzymes has been implicated in a range of human diseases, including cancer, Parkinson's disease, myotonic dystrophy, and developmental defects.

Cytochrome p450

An example of a phase I drug-metabolizing enzyme is the cytochrome p450 ("CYP") superfamily, the members of which comprise the major drug-metabolizing enzymes expressed in the liver. The CYP superfamily comprises heme proteins which catalyze the oxidation and dehydrogenation of a number of endogenous and exogenous lipophilic compounds. The CYP superfamily has immense diversity in its functions, with hundreds of isoforms in many species catalyzing many types of chemical reactions. The CYP superfamily comprises at least 30 related enzymes, which are divided into different families according to their amino acid homology. Examples of CYP families include CYP families 1, 2, 3 and 4, which comprise endoplasmic reticulum proteins responsible for the metabolism of drugs and other xenobiotics. Approximately 10-15 individual gene products within these four families metabolize thousands of structurally diverse compounds. It is estimated that collectively the enzymes in the CYP superfamily participate in the metabolism of greater than 80% of all available drugs used in humans. For example, the CYP 1A subfamily comprises CYP 1A2, which metabolizes several widely used drugs, including acetaminophen, amitriptyline, caffeine, clozapine, haloperidol, imipramine, olanzapine, ondansetron, phenacetin, propafenone, propranolol, tacrine, theophylline, verapamil. In addition, CYP enzymes play additional roles in the metabolism of some endogenous substrates including prostaglandins and steroids.

Some CYP enzymes exist in a polymorphic form, meaning that a small percentage of the population possesses mutant genes that alter the activity of the enzyme, usually by diminishing or abolishing activity. For example, a genetic polymorphism has been well characterized with the CYP 2C19 and CYP 2D6 genes. Substrates of CYP 2C19 include clomipramine, diazepam, imipramine, mephenytoin, moclobemide, omeprazole, phenytoin, propranolol, and tolbutamide. Substrates of CYP 2D6 include alprenolol, amitriptyline, chlorpheniramine, clomipramine, codeine, desipramine, dextromethorphan, encainide, fluoxetine, haloperidol, imipramine, indoramin, metoprolol, nortriptyline, ondansetron,

oxycodone, paroxetine, propranolol, and propafenone. Polymorphic variants of these genes metabolize these substrates at different rates, which can effect a patient's effective therapeutic dosage.

While the substrate specificity of CYPs must be very broad to accommodate the metabolism of all of these compounds, each individual CYP gene product has a narrower substrate specificity defined by its binding and catalytic sites. Drug metabolism can thereby be regulated by changes in the amount or activity of specific CYP gene products. Methods of CYP regulation include genetic differences in the expression of CYP gene products (i.e., genetic polymorphisms), inhibition of CYP metabolism by other xenobiotics that also bind to the CYP, and induction of certain CYPs by the drug itself or other xenobiotics. Inhibition and induction of CYPs is one of the most common mechanisms of adverse drug interactions. For example, the CYP3A subfamily is involved in clinically significant drug interactions involving nonsedating antihistamines and cisapride that may result in cardiac dysrhythmias. In another example, CYP3A4 and CYP1A2 enzymes are involved in drug interactions involving theophylline. In yet another example, CYP2D6 is responsible for the metabolism of many psychotherapeutic agents. Additionally, CYP enzymes metabolize the protease inhibitors used to treat patients infected with the human immunodeficiency virus. By understanding the unique functions and characteristics of these enzymes, physicians may better anticipate and manage drug interactions and may predict or explain an individual's response to a particular therapeutic regimen.

Examples of reactions catalyzed by the CYP superfamily include peroxidative reactions utilizing peroxides as oxygen donors in hydroxylation reactions, as substrates for reductive beta-scission, and as peroxyhemiacetal intermediates in the cleavage of aldehydes to formate and alkenes. Lipid hydroperoxides undergo reductive beta-cleavage to give hydrocarbons and aldehydic acids. One of these products, trans-4-hydroxynonenal, inactivates CYP, particularly alcohol-inducible 2E1, in what may be a negative regulatory process. Although a CYP iron-oxene species is believed to be the oxygen donor in most hydroxylation reactions, an iron-peroxy species is apparently involved in the deformylation of many aldehydes with desaturation of the remaining structure, as in aromatization reactions.

Examples of drugs with oxidative metabolism associated with CYP enzymes include acetaminophen, alfentanil, alprazolam, alprenolol, amiodarone, amitriptyline, astemizole, buspirone, caffeine, carbamazepine, chlorpheniramine, cisapride, clomipramine, clomipramine, clozapine, codeine, colchicine, cortisol, cyclophosphamide, cyclosporine,

dapsone, desipramine, dextromethorphan, diazepam, diclofenac, diltiazem, encainide, erythromycin, estradiol, felodipine, fluoxetine, fluvastatin, haloperidol, ibuprofen, imipramine, indinavir, indomethacin, indoramin, irbesartan, lidocaine, losartan, macrolide antibiotics, mephenytoin, methadone, metoprolol, mexilitene, midazolam, moclobemide, naproxen, nefazodone, nicardipine, nifedipine, nitrendipine, nortriptyline, olanzapine, omeprazole, ondansetron, oxycodone, paclitaxel, paroxetine, phenacetin, phenytoin, piroxicam, progesterone, propafenone, propranolol, quinidine, ritonavir, saquinavir, sertraline, sildenafil, S-warfarin, tacrine, tamoxifen, tenoxicam, terfenadine, testosterone, theophylline, timolol, tolbutamide, triazolam, verapamil, and vinblastine.

Abnormal activity of phase I enzymes has been implicated in a range of human diseases. For example, enhanced CYP2D6 activity has been related to malignancies of the bladder, liver, pharynx, stomach and lungs, whereas decreased CYP2D activity has been linked to an increased risk of Parkinson's disease. Other syndromes and developmental defects associated with deficiencies in the CYP superfamily include cerebrotendinous xanthomatosis, adrenal hyperplasia, gynecomastia, and myotonic dystrophy.

The CYP superfamily a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of the CYP superfamily.

UDP-glucuronosyltransferases

Potential drug interactions involving phase II metabolism are increasingly being recognized. An important group of phase II enzymes involved in drug metabolism are the glucuronosyltransferases, especially the UDP-glucuronosyltransferase ("UGT") superfamily. Members of the UGT superfamily catalyze the enzymatic addition of UDP glucuronic acid as a sugar donor to fat-soluble chemicals, a process which increases their solubility in water and increases their rate of excretion. In mammals, glucuronic acid is the main sugar that is used to prevent the accumulation of waste products of metabolism and fat-soluble chemicals from the environment to toxic levels in the body. Both inducers and inhibitors of glucuronosyltransferases are known and have the potential to affect the plasma concentration and actions of important drugs, including psychotropic drugs.

The UGT superfamily comprises several families of enzymes in several species defined with a nomenclature similar to that used to define members of the CYP superfamily. In animals, yeast, plants and bacteria there are at least 110 distinct known members of the

UGT superfamily. As many as 33 families have been defined, with three families identified in humans. Different UGT families are defined as having <45% amino acid sequence homology; within subfamilies there is approximately 60% homology. The members of the UGT superfamily are part of a further superfamily of UDP glycosyltransferases found in animals, plants and bacteria.

The role of phase II enzymes, and of UGT enzymes in particular, is being increasingly recognized as important in psychopharmacology. UGT enzymes conjugate many important psychotropic drugs and are an important source of variability in drug response and drug interactions. For example, the benzodiazepines lorazepam, oxazepam, and temazepam undergo phase II reactions exclusively before being excreted into the urine.

Phase II enzymes metabolize and detoxify hazardous substances, such as carcinogens. The expression of genes encoding phase II enzymes is known to be up-regulated by hundreds of agents. For example, oltipraz is known to up-regulate phase II enzyme expression. Studies have demonstrated protection from the cancer-causing effects of carcinogens when selected phase II enzyme inducers are administered prior to the carcinogens. The potential use of phase II enzyme inducers in humans for prevention of cancers related to exposure to carcinogens has prompted studies aimed at understanding their molecular effects. Current biochemical and molecular biological research methodologies can be used to identify and characterize selective phase II enzyme inducers and their targets. Identification of genes responding to cancer chemopreventive agents will facilitate studies of their basic mechanism and provide insights about the relationship between gene regulation, enzyme polymorphism, and carcinogen detoxification.

Examples of drugs with conjugative metabolism associated with UGT enzymes include amitriptyline, buprenorphine, chlorpromazine, clozapine, codeine, cyproheptadine, dihydrocodeine, doxepin, imipramine, lamotrigine, lorazepam, morphine, nalorphine, naltrexone, temazepam, and valproate.

Abnormal activity of phase II enzymes has been implicated in a range of human diseases. For example, Gilbert syndrome is an autosomal dominant disorder caused by mutation in the UGT1 gene, and mutations in the UGT1A1 enzyme have been demonstrated to be responsible for Crigler-Najjar syndrome.

The UGT superfamily a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of the UGT superfamily.

For a further review of UDP-glucuronosyltransferases, see Jin et al., *Biochem Biophys Res Commun* 1993 Jul 15;194(1):496-503; Beaulieu et al., *Biochem Biophys Res Commun* 1998 Jul 9;248(1):44-50; Belanger et al., *DNA Cell Biol* 1997 Oct;16(10):1195-205; Jackson et al., *Biochem J* 1987 Mar 1;242(2):581-8; Taura et al., *Biochem Biophys Res Commun* 2000 Jul 14;273(3):1048-1052; Burchell et al., *DNA Cell Biol.* 10: 487-494, 1991; Krasnewich et al., *Somat. Cell Molec. Genet.* 13: 179-182, 1987; Monaghan et al., *Genomics* 23: 496-499, 1994; Monaghan et al., *Genomics* 13: 908-909, 1992; and Riedy et al., *Pharmacogenetics* 10: 251-260, 2000.

Drug-metabolizing enzymes, particularly members of the UDP-glucuronosyltransferase drug-metabolizing enzyme subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of drug-metabolizing proteins. The present invention advances the state of the art by providing a previously unidentified human drug-metabolizing proteins that have homology to members of the UDP-glucuronosyltransferase drug-metabolizing enzyme subfamily.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human drug-metabolizing enzyme peptides and proteins that are related to the UDP-glucuronosyltransferase drug-metabolizing enzyme subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate drug-metabolizing enzyme activity in cells and tissues that express the drug-metabolizing enzyme. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium.

DESCRIPTION OF THE FIGURE SHEETS

FIGURE 1 provides the nucleotide sequence of a cDNA molecule that encodes the drug-metabolizing enzyme protein of the present invention. (SEQ ID NO:1) In addition,

structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium.

FIGURE 2 provides the predicted amino acid sequence of the drug-metabolizing enzyme of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIGURE 3 provides genomic sequences that span the gene encoding the drug-metabolizing enzyme protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in Figure 3, SNPs were identified at 17 different nucleotide positions.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a drug-metabolizing enzyme protein or part of a drug-metabolizing enzyme protein and are related to the UDP-glucuronosyltransferase drug-metabolizing enzyme subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human drug-metabolizing enzyme peptides and proteins that are related to the UDP-glucuronosyltransferase drug-metabolizing enzyme subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these drug-metabolizing enzyme peptides and proteins, nucleic acid variation (allelic information),

tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the drug-metabolizing enzyme of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known drug-metabolizing enzyme proteins of the UDP-glucuronosyltransferase drug-metabolizing enzyme subfamily and the expression pattern observed. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known UDP-glucuronosyltransferase family or subfamily of drug-metabolizing enzyme proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the drug-metabolizing enzyme family of proteins and are related to the UDP-glucuronosyltransferase drug-metabolizing enzyme subfamily (protein sequences are provided in Figure 2, transcript/cDNA sequences are provided in Figure 1 and genomic sequences are provided in Figure 3). The peptide sequences provided in Figure 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in Figure 3, will be referred herein as the drug-metabolizing enzyme peptides of the present invention, drug-metabolizing enzyme peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the drug-metabolizing enzyme peptides disclosed in the Figure 2, (encoded by the nucleic acid molecule shown in Figure 1,

transcript/cDNA or Figure 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the drug-metabolizing enzyme peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated drug-metabolizing enzyme peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. For example, a nucleic acid molecule encoding the drug-metabolizing enzyme peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in Figure 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the drug-metabolizing enzyme peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The drug-metabolizing enzyme peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a drug-metabolizing enzyme peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the drug-metabolizing enzyme peptide. "Operatively linked" indicates that the drug-metabolizing enzyme peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the drug-metabolizing enzyme peptide.

In some uses, the fusion protein does not affect the activity of the drug-metabolizing enzyme peptide *per se*. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant drug-metabolizing enzyme peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A drug-metabolizing enzyme peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the drug-metabolizing enzyme peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the drug-metabolizing enzyme peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be

introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part 1*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., *et al.*, *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the drug-metabolizing enzyme peptides of the present invention as well as being encoded by the same genetic locus as the drug-metabolizing enzyme peptide provided herein. The gene encoding the novel drug-metabolizing protein of the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Allelic variants of a drug-metabolizing enzyme peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the drug-metabolizing enzyme peptide as well as being encoded by the same genetic locus as the drug-metabolizing enzyme peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in Figure 3, such as the genomic sequence mapped to the reference human. The gene encoding the novel drug-metabolizing protein of the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a drug-metabolizing enzyme

peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

Figure 3 provides information on SNPs that have been found in the gene encoding the drug-metabolizing protein of the present invention. SNPs were identified at 17 different nucleotide positions. Some of these SNPs may affect control/regulatory elements.

Paralogs of a drug-metabolizing enzyme peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the drug-metabolizing enzyme peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a drug-metabolizing enzyme peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a drug-metabolizing enzyme peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the drug-metabolizing enzyme peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a drug-metabolizing enzyme peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the drug-metabolizing enzyme peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the drug-metabolizing enzyme peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a drug-metabolizing enzyme peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

Variant drug-metabolizing enzyme peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Figure 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 244:1081-1085 (1989)), particularly using the results provided in Figure 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as drug-metabolizing enzyme activity or in assays such as an *in vitro* proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.* *Science* 255:306-312 (1992)).

The present invention further provides fragments of the drug-metabolizing enzyme peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in Figure 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a drug-metabolizing enzyme peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the drug-metabolizing enzyme peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the drug-metabolizing enzyme peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include,

but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in Figure 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in drug-metabolizing enzyme peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in Figure 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

Accordingly, the drug-metabolizing enzyme peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature drug-metabolizing enzyme peptide is fused with another compound, such as a compound to increase

the half-life of the drug-metabolizing enzyme peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature drug-metabolizing enzyme peptide, such as a leader or secretory sequence or a sequence for purification of the mature drug-metabolizing enzyme peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a drug-metabolizing enzyme-effector protein interaction or drug-metabolizing enzyme-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, drug-metabolizing enzymes isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the drug-metabolizing enzyme. Experimental data as provided in Figure 1 indicates that the drug-metabolizing proteins of the present invention are expressed in humans in the kidney (including kidney hypernephromas), liver (including HepG2 cell lines and hepatocellular carcinomas), and pigmented retinal epithelium, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in human

fetal liver. A large percentage of pharmaceutical agents are being developed that modulate the activity of drug-metabolizing enzyme proteins, particularly members of the UDP-glucuronosyltransferase subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in Figure 1. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The drug-metabolizing enzyme polypeptides (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to drug-metabolizing enzymes that are related to members of the UDP-glucuronosyltransferase subfamily. Such assays involve any of the known drug-metabolizing enzyme functions or activities or properties useful for diagnosis and treatment of drug-metabolizing enzyme-related conditions that are specific for the subfamily of drug-metabolizing enzymes that the one of the present invention belongs to, particularly in cells and tissues that express the drug-metabolizing enzyme. Experimental data as provided in Figure 1 indicates that the drug-metabolizing proteins of the present invention are expressed in humans in the kidney (including kidney hypernephromas), liver (including HepG2 cell lines and hepatocellular carcinomas), and pigmental retinal epithelium, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in human fetal liver.

The drug-metabolizing enzyme polypeptides are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the drug-metabolizing enzyme, as a biopsy or expanded in cell culture. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the drug-metabolizing enzyme protein.

The polypeptides can be used to identify compounds that modulate drug-metabolizing enzyme activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the drug-metabolizing enzyme. Both the drug-metabolizing enzymes of the present invention and appropriate variants and fragments can be used in high-

throughput screens to assay candidate compounds for the ability to bind to the drug-metabolizing enzyme. These compounds can be further screened against a functional drug-metabolizing enzyme to determine the effect of the compound on the drug-metabolizing enzyme activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the drug-metabolizing enzyme to a desired degree.

Further, the drug-metabolizing enzyme polypeptides can be used to screen a compound for the ability to stimulate or inhibit interaction between the drug-metabolizing enzyme protein and a molecule that normally interacts with the drug-metabolizing enzyme protein. Such assays typically include the steps of combining the drug-metabolizing enzyme protein with a candidate compound under conditions that allow the drug-metabolizing enzyme protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the drug-metabolizing enzyme protein and the target.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang *et al.*, *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant drug-metabolizing enzymes or appropriate fragments containing mutations that affect drug-metabolizing enzyme function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

Any of the biological or biochemical functions mediated by the drug-metabolizing enzyme can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by

reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly Figure 2. Specifically, a biological function of a cell or tissues that expresses the drug-metabolizing enzyme can be assayed. Experimental data as provided in Figure 1 indicates that the drug-metabolizing proteins of the present invention are expressed in humans in the kidney (including kidney hypernephromas), liver (including HepG2 cell lines and hepatocellular carcinomas), and pigmental retinal epithelium, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in human fetal liver.

Binding and/or activating compounds can also be screened by using chimeric drug-metabolizing enzyme proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is recognized by the native drug-metabolizing enzyme. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the drug-metabolizing enzyme is derived.

The drug-metabolizing enzyme polypeptides are also useful in competition binding assays in methods designed to discover compounds that interact with the drug-metabolizing enzyme (e.g. binding partners and/or ligands). Thus, a compound is exposed to a drug-metabolizing enzyme polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble drug-metabolizing enzyme polypeptide is also added to the mixture. If the test compound interacts with the soluble drug-metabolizing enzyme polypeptide, it decreases the amount of complex formed or activity from the drug-metabolizing enzyme target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the drug-metabolizing enzyme. Thus, the soluble polypeptide that competes with the target drug-metabolizing enzyme region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the drug-metabolizing enzyme protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ^{35}S -labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of drug-metabolizing enzyme-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a drug-metabolizing enzyme-binding protein and a candidate compound are incubated in the drug-metabolizing enzyme protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the drug-metabolizing enzyme protein target molecule, or which are reactive with drug-metabolizing enzyme protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the drug-metabolizing enzymes of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of drug-metabolizing enzyme protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the drug-metabolizing enzyme pathway, by treating cells or tissues that express the drug-metabolizing enzyme. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and

hepatocellular carcinomas), and pigmental retinal epithelium. These methods of treatment include the steps of administering a modulator of drug-metabolizing enzyme activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the drug-metabolizing enzyme proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the drug-metabolizing enzyme and are involved in drug-metabolizing enzyme activity. Such drug-metabolizing enzyme-binding proteins are likely to be drug-metabolizing enzyme inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a drug-metabolizing enzyme protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a drug-metabolizing enzyme-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the drug-metabolizing enzyme protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a drug-metabolizing enzyme-modulating agent, an antisense drug-metabolizing enzyme nucleic acid molecule, a drug-metabolizing enzyme-specific antibody, or a drug-metabolizing enzyme-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an

agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The drug-metabolizing enzyme proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. The method involves contacting a biological sample with a compound capable of interacting with the drug-metabolizing enzyme protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered drug-metabolizing enzyme activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected *in vivo* in a subject by introducing into the subject a labeled anti-peptide antibody or other types

of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M.W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the drug-metabolizing enzyme protein in which one or more of the drug-metabolizing enzyme functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and drug-metabolizing enzyme activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal

epithelium. Accordingly, methods for treatment include the use of the drug-metabolizing enzyme protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, *Antibodies*, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in Figure 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the drug-metabolizing enzyme proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or drug-metabolizing enzyme/binding partner interaction. Figure 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see Figure 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in Figure 1 indicates that the drug-metabolizing proteins of the present invention are expressed in humans in the kidney (including kidney hypernephromas), liver (including HepG2 cell lines and hepatocellular carcinomas), and pigmental retinal epithelium, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in human fetal liver. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological

condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the drug-metabolizing enzyme peptide to a binding partner such as a substrate. These

uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See Figure 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a drug-metabolizing enzyme peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the drug-metabolizing enzyme peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In Figures 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (Figure 3) and cDNA/transcript sequences (Figure 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in Figures 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the drug-metabolizing enzyme peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants

of the drug-metabolizing enzyme proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in Figures 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in Figure 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could be at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure

sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. The gene encoding the novel drug-metabolizing protein of the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Figure 3 provides information on SNPs that have been found in the gene encoding the drug-metabolizing protein of the present invention. SNPs were identified at 17 different nucleotide positions. Some of these SNPs may affect control/regulatory elements.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in Figure 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in Figure 2. As illustrated in Figure 3, SNPs were identified at 17 different nucleotide positions.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter *in situ* expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of *in situ* hybridization methods. The gene encoding the novel drug-metabolizing protein of the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in Figure 1 indicates that the drug-metabolizing proteins of the present invention are expressed in humans in the kidney (including kidney hypernephromas), liver (including HepG2 cell lines and hepatocellular carcinomas), and pigmental retinal epithelium, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in human fetal

liver. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in drug-metabolizing enzyme protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA include Southern hybridizations and *in situ* hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a drug-metabolizing enzyme protein, such as by measuring a level of a drug-metabolizing enzyme-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a drug-metabolizing enzyme gene has been mutated. Experimental data as provided in Figure 1 indicates that the drug-metabolizing proteins of the present invention are expressed in humans in the kidney (including kidney hypernephromas), liver (including HepG2 cell lines and hepatocellular carcinomas), and pigmental retinal epithelium, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in human fetal liver.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate drug-metabolizing enzyme nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the drug-metabolizing enzyme gene, particularly biological and pathological processes that are mediated by the drug-metabolizing enzyme in cells and tissues that express it. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium. The method typically includes assaying the ability of the compound to modulate the expression of the drug-metabolizing enzyme nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired drug-metabolizing enzyme nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the drug-metabolizing enzyme nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

Thus, modulators of drug-metabolizing enzyme gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of drug-metabolizing enzyme mRNA in the presence of the candidate compound is compared to the level of expression of drug-metabolizing enzyme mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate drug-metabolizing enzyme nucleic acid expression in cells and tissues that express the drug-metabolizing enzyme. Experimental data as provided in Figure 1 indicates that the drug-metabolizing proteins of the present invention are expressed in humans in the kidney (including kidney hypernephromas), liver (including HepG2 cell lines and hepatocellular carcinomas), and pigmental retinal epithelium, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in human fetal liver. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for drug-metabolizing enzyme nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the drug-metabolizing enzyme nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in Figure 1 indicates expression in humans in the kidney (including kidney hypernephromas), liver (including fetal liver, HepG2 cell lines, and hepatocellular carcinomas), and pigmental retinal epithelium.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the drug-metabolizing enzyme gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also

serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in drug-metabolizing enzyme nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in drug-metabolizing enzyme genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the drug-metabolizing enzyme gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the drug-metabolizing enzyme gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a drug-metabolizing enzyme protein.

Individuals carrying mutations in the drug-metabolizing enzyme gene can be detected at the nucleic acid level by a variety of techniques. Figure 3 provides information on SNPs that have been found in the gene encoding the drug-metabolizing protein of the present invention. SNPs were identified at 17 different nucleotide positions. Some of these SNPs may affect control/regulatory elements. The gene encoding the novel drug-metabolizing protein of the present invention is located on a genome component that has been mapped to human chromosome 4 (as indicated in Figure 3), which is supported by multiple lines of evidence, such as STS and BAC map data. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells

from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a drug-metabolizing enzyme gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant drug-metabolizing enzyme gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C.W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*, *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the drug-metabolizing enzyme gene in an individual in order to select an appropriate compound or dosage regimen for treatment. Figure 3 provides information on SNPs that have been found in the gene encoding the drug-metabolizing protein of the present invention. SNPs were identified at 17 different nucleotide positions. Some of these SNPs may affect control/regulatory elements.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control drug-metabolizing enzyme gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of drug-metabolizing enzyme protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into drug-metabolizing enzyme protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of drug-metabolizing enzyme nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired drug-metabolizing enzyme nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the drug-metabolizing enzyme protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in drug-metabolizing enzyme gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired drug-metabolizing enzyme protein to treat the individual.

The invention also encompasses kits for detecting the presence of a drug-metabolizing enzyme nucleic acid in a biological sample. Experimental data as provided in Figure 1 indicates that the drug-metabolizing proteins of the present invention are expressed in humans in the kidney (including kidney hypernephromas), liver (including HepG2 cell lines and hepatocellular carcinomas), and pigmental retinal epithelium, as indicated by virtual northern blot analysis. In addition, PCR-based tissue screening panels indicate expression in human fetal liver. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting drug-metabolizing enzyme nucleic acid in a biological sample; means for determining the amount of drug-metabolizing enzyme nucleic acid in the sample; and means for comparing the amount of drug-metabolizing enzyme nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect drug-metabolizing enzyme protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in Figures 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in US Patent 5,837,832, Chee *et al.*, PCT application W095/11995 (Chee *et al.*), Lockhart, D. J. *et al.* (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. *et al.* (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown *et al.*, US Patent No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential

oligonucleotides that cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al.*) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that

hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the drug-metabolizing enzyme proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the drug-metabolizing enzyme gene of the present invention. Figure 3 provides information on SNPs that have been found in the gene encoding the drug-metabolizing protein of the present invention. SNPs were identified at 17 different nucleotide positions. Some of these SNPs may affect control/regulatory elements.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. *et al.*, *Techniques in Immunocytochemistry*, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to

be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified drug-metabolizing enzyme gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/host cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector

may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived

from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the

target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed.*, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein,

including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, *et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989)*.

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and

translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a drug-metabolizing enzyme protein or peptide that can be further purified to produce desired amounts of drug-metabolizing enzyme protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the drug-metabolizing enzyme protein or drug-metabolizing enzyme protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native drug-metabolizing enzyme protein is useful for assaying compounds that stimulate or inhibit drug-metabolizing enzyme protein function.

Host cells are also useful for identifying drug-metabolizing enzyme protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant drug-metabolizing enzyme protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native drug-metabolizing enzyme protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a drug-metabolizing enzyme protein and identifying and evaluating modulators of drug-metabolizing enzyme protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the drug-metabolizing enzyme protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the drug-metabolizing enzyme protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the

cre/loxP recombinase system, see, e.g., Lakso *et al.* *PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al.* *Science* 251:1351-1355 (1991). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al.* *Nature* 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could effect substrate binding, drug-metabolizing enzyme protein activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* drug-metabolizing enzyme protein function, including substrate interaction, the effect of specific mutant drug-metabolizing enzyme proteins on drug-metabolizing enzyme protein function and substrate interaction, and the effect of chimeric drug-metabolizing enzyme proteins. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely eliminate one or more drug-metabolizing enzyme protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of

the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

Claims

That which is claimed is:

1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
2. An isolated peptide comprising an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
3. An isolated antibody that selectively binds to a peptide of claim 2.

4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

6. A gene chip comprising a nucleic acid molecule of claim 5.

7. A transgenic non-human animal comprising a nucleic acid molecule of claim 5.
8. A nucleic acid vector comprising a nucleic acid molecule of claim 5.
9. A host cell containing the vector of claim 8.
10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.

16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.

17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.

18. A method for treating a disease or condition mediated by a human drug-metabolizing enzyme protein, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim 16.

19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.

20. An isolated human drug-metabolizing enzyme peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.

21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.

22. An isolated nucleic acid molecule encoding a human drug-metabolizing enzyme peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

1/17

```

1 CAACCATTGC AGATCAGTGT GTGAGGGAAC TGCCATCATG AGGTCTGACA
51 AGTCAGCTTT GGTATTTCTG CTCCTGCAGC TCTTCTGTGT TGGCTGTGGA
101 TTCTGTGGGA AAGTCCTGGT GTGGCCCTGT GACATGAGCC ATTGGCTTAA
151 TGTCGAAGTC ATTCTAGAAG AGCTCATAGT GAGAGGCCAT GAGGTAACAG
201 TATTGACTCA CTCAAAGCCT TCGTTAATTG ACTACAGGAA GCCTTCTGCA
251 TTGAAATTTG AGGTGGTCCA TATGCCACAG GACAGAACAG AAGAAAATGA
301 AATATTTGTT GACCTAGCTC TGAATGTCTT GCCAGGCTTA TCAACCTGGC
351 AATCAGTTAT AAAATTAAAT GATTTTTTTG TTGAAATAAG AGGAACTTTA
401 AAAATGATGT GTGAGAGCTT TATCTACAAT CAGACGCTTA TGAAGAAGCT
451 ACAGGAAACC AACTACGATG TAATGCTTAT AGACCCTGTG ATTCCTGTG
501 GAGACCTGAT GGCTGAGTTG CTTGCACTCC CTTTGTGCT CACACTAGA
551 ATTTCTGTAG GAGGCAATAT GGAGCGAAGC TGTGGGAAAC TTCCAGCTCC
601 ACTTTCTAT GTACCTGTGC CTATGACAGG ACTAACAGAC AGAATGACCT
651 TTCTGGAAAG AGTAAAAAAT TCAATGCTTT CAGTTTTGTT CCACTTCTGG
701 ATTCAGGATT ACGACTATCA TTTTGGGAA GAGTTTTATA GTAAGGCATT
751 AGGAAGGCCC ACTACATTAT GTGAGACTGT GGGAAAAGCT GAGATATGGC
801 TAATACGAAC ATATTGGGAT TTGAATTTT CTAACCATA CCAACCTAAC
851 TTGAGTTTG TTGGAGGATT GCACTGTAAA CCTGCCAAG CTTTGCCTAA
901 GGAAATGGAA AATTTTGTCC AGAGTTCAGG GGAAGATGGT ATTGTGGTGT
951 TTTCTCTGGG GTCACGTGTT CAAAATGTTA CAGAAGAAAA GGCTAATATC
1001 ATTGCTTCAG CCCTTGCCCA GATCCCACAG AAGGTGTTAT GGAGGTACAA
1051 AGGAAAAAAA CCATCCACAT TAGGAGCCAA TACTCGGCTG TATGATTGGA
1101 TACCCAGAAA TGATCTTCTT GGTCACTCCA AAACCAAGC TTTTATCACT
1151 CATGGTGGAA TGAATGGGAT CTATGAAGCT ATTTACCATG GGGTCCCTAT
1201 GGTGGGAGTT CCCATATTG GTGATCAGCT TGATAACATA GCTCACATGA
1251 AGGCCAAAGG AGCAGCTGTA GAAATAAAT TCAAACTAT GACAAGCGAA
1301 GATTTACTGA GGGCTTGAAG AACAGTCATT ACCGATTCTT CTTATAAAGA
1351 GAATGCTATG AGATTATCAA GAATTCACCA TGATCAACCT GTAAAGCCCC
1401 TAGATCGAGC AGTCTTCTGG ATCGAGTTG TCATGCGCCA CAAAGGAGCC
1451 AAGCACCTGC GATCAGCTGC CCATGACCTC ACCTGGTTC AGCACTACTC
1501 TATAGATGTG ATTGGGTTC TGCTGACCTG TGTGGCAACT GCTATATTCT
1551 TGTTCACAAA ATGTTTTTTA TTTTCTGTC AAAAAATTAA TAAACTAGA
1601 AAGATAGAAA AGAGGGAATA GATCTTTCCA AATTCAAGAA AGACCTGATG
1651 GGGTAATCCT GTTAATTCCA GCCACATAGA ATTTGGTGAA AACCTTGCTA
1701 TTTTCATATT ATCTATTCTG TTATTTTATC TTAGCTATAT AGCCTAGAAT
1751 TCCATGATCA TGAGGTTGTG AGTATATCTC ATTCTTTCGT TGCATTTTCC
1801 TAGGTGTGCT TACTCTCTTC TCTCACTTG TGACACAAGG ACATGAATAC
1851 ATCTAAATTT TCCTATTTCT GATATCACTG TTTCCATGAC GTCATTACTT
1901 CTCTAACCTT AAGTGATAGG GTGACCTGCA ATATGCTGAT TCCTGGTGT
1951 TGCACAAACA CATGGATGTA AAGAAGTAAA AAATGTAAAA TTCACAAAAT
2001 TCAGTAAACC ACACAAATCA ATGAAGCATT CTATGACATT AGCTTGTTAT
2051 GAGTAACATA ATGATTTTTC TTTTCAATT TAAATAAGCC CTTCTACATA
2101 CCCAGCATT CTGATCTCAG ACAATGAATT GCTAAAAATG ACGATAGGGC
2151 ATTACACTCA GAATAGTTTG CTATATTTC ACATACCTCA TCTAGATGTC
2201 ATAGCCTACA TTTCTGCCAT CACTTAACTG ACATTTTTTG TGTGTTCTTG
2251 ATGATAAATA GACAGTTCTT ATTATTGTCC TCAATAATA AAAGAACTG
2301 AAATTTTCTT ACATAGAGAA AATGTCCATA AGATATTCAA GTTAAACAGA
2351 TTATTTTGAG ATAAGTAACC ATTAGAAATA TGTGATTGTA ATTTCTGATT
2401 TTATAAAATT TTAATTGATA GTACACTTGA TTAAATGTC TATTCTTTAA
2451 AATGATGAAT ACTCATAATT CTTATCTCTA TAATCAAAAG TATAATTTAC
2501 TGTAGAAAAA TAAAGAGATG CTTGTTCTGA AAGTAAAAAA AAAAAAAAAA
2551 AAAACACTGT CATGCCGTTA CGTAGCGTAT CGTTGACAGC CCACTGTCAT
2601 GCCGTACGT AGCATATCGT TGACAGCGAC ACTGTCATGC CGTTACGTAG
2651 CGTATCGTTG ACAGCACTGT CATGCGTTAC GAGCGTATCG TTGACAGCAC
2701 TGTCAAGCCG TTACGTAGCG TATCGTTGAC AGCAAAACAC TGTACGCCGT
2751 TACGTAGCG (SEQ ID NO:1)

```

FEATURES:

```

5'UTR:      1-37
Start Codon: 38
Stop Codon:  1619
3'UTR:      1622

```

FIGURE 1, page 1 of 2

2/17

Homologous proteins:Top 10 BLAST Hits

	Score	E
CRA 147000022596013 /altid=gi 10438148 /def=dbj BAB15179.1 (AK...	931	0.0
CRA 1000682322899 /altid=gi 5802604 /def=gb AAD51732.1 (AF1752...	795	0.0
CRA 335001098690982 /altid=gi 11436851 /def=ref XP_003547.1 UD...	679	0.0
CRA 18000005226060 /altid=gi 5803213 /def=ref NP_006789.1 UDP ...	677	0.0
CRA 18000005155438 /altid=gi 4507821 /def=ref NP_001068.1 UDP ...	676	0.0
CRA 18000005147363 /altid=gi 6175083 /def=sp P06133 UDB4_HUMAN ...	675	0.0
CRA 18000004953169 /altid=gi 484383 /def=pir JN0619 glucuronos...	674	0.0
CRA 18000005148770 /altid=gi 3153832 /def=gb AAC95002.1 (AF064...	674	0.0
CRA 18000004903910 /altid=gi 4507819 /def=ref NP_001067.1 UDP ...	669	0.0
CRA 18000005164461 /altid=gi 3426332 /def=gb AAC32272.1 (AF081...	668	0.0
CRA 1000682327923 /altid=gi 5881246 /def=gb AAD55093.1 AF180322...	668	0.0
CRA 18000005219476 /altid=gi 8134780 /def=sp Q9XT55 UDBJ_MACFA ...	667	0.0

BLAST dbEST hits:

gi 10971169 /dataset=dbest /taxon=96...	383	e-103
gi 11068678 /dataset=dbest /taxon=96...	234	6e-59
gi 679005 /dataset=dbest /taxon=9606 /...	212	2e-52
gi 3173232 /dataset=dbest /taxon=9606 ...	212	2e-52
gi 3134358 /dataset=dbest /taxon=9606 ...	212	2e-52
gi 10298020 /dataset=dbest /taxon=96...	200	8e-49
gi 11974507 /dataset=dbest /taxon=96...	196	1e-47
gi 11973717 /dataset=dbest /taxon=96...	172	2e-40
gi 12673874 /dataset=dbest /taxon=96...	137	1e-29
gi 10887798 /dataset=dbest /taxon=96...	125	4e-26

EXPRESSION INFORMATION FOR MODULATORY USE:library source:Expression information from BLAST dbEST hits:

gi|10971169 Kidney-hypernephroma
gi|11068678 HepG2 cell line
gi|679005 Liver
gi|3173232 Kidney
gi|3134358 Kidney
gi|10298020 Hepatocellular carcinoma
gi|11974507 Normal pigmental retinal epithelium
gi|11973717 Normal pigmental retinal epithelium
gi|12673874 Kidney hypernephroma
gi|10887798 Kidney

Expression information from PCR-based tissue screening panels:

Human fetal liver

3/17

```

1 MRSDKSALVF LLLQLFCVGC GFCGKVLVWP CDMSHWLNVK VILEELIVRG
51 HEVTVLTHSK PSLIDYRKPS ALKFEVVHMP QDRTEENEIF VDLALNVLPG
101 LSTWQSVIKL NDFVVEIRGT LKMMCESFIY NQTLMKKLQE TNYDVMLIDP
151 VIPCGDLMAE LLAVPFVLTLL RISVGGNMER SCGKLPAPLS YVFPVMTGLT
201 DRMTFLERVK NSMLSVLFHF WIQDYDYHFW EEFYSKALGR PTTLCETVGK
251 AEIWLIRTYW DFEFPQPYQP NFEFVGGLHC KPAKALPKEM ENFVQSSGED
301 GIVVFSLGSL FQNVTEEKAN IASALAQIP QKVLWRYK GK KPSTLGANTR
351 LYDWIPQNDL LGHPKTKAFI THGGMNGIYE AIYHGVPMVG VPIFGDQLDN
401 IAHMKAKGAA VEINFKTMTS EDLLRALRTV ITDSSYKENA MRLSRIHHDQ
451 PVKPLDRAVF WIEFVMRHKG AKHLRSAHD LTWFQHSID VIGFLLTCVA
501 TAIFLFTKCF LFSCQKFNKT RKIEKRE (SEQ ID NO:2)

```

FEATURES:**Functional domains and key regions:**

[1] PDOC00001 PS00001 ASN_GLYCOSYLATION
N-glycosylation site

Number of matches: 3

```

1      131-134 NQTL
2      313-316 NVTE
3      518-521 NKTR

```

[2] PDOC00004 PS00004 CAMP_PHOSPHO_SITE
cAMP- and cGMP-dependent protein kinase phosphorylation site

Number of matches: 2

```

1      67-70 RKPS
2      340-343 KKPS

```

[3] PDOC00005 PS00005 PKC_PHOSPHO_SITE
Protein kinase C phosphorylation site

Number of matches: 6

```

1      3-5 SDK
2      120-122 TLK
3      169-171 TLR
4      200-202 TDR
5      435-437 SYK
6      520-522 TRK

```

[4] PDOC00006 PS00006 CK2_PHOSPHO_SITE
Casein kinase II phosphorylation site

Number of matches: 9

```

1      62-65 SLID
2      141-144 TNYD
3      204-207 TFLE
4      243-246 TLCE
5      258-261 TYWD
6      296-299 SSGE
7      297-300 SGED
8      419-422 TSED
9      435-438 SYKE

```

[5] PDOC00007 PS00007 TYR_PHOSPHO_SITE
Tyrosine kinase phosphorylation site

Number of matches: 2

```

1      122-130 KMMCESFIY
2      136-143 KKLQETNY

```

4/17

[6] PDOC00008 PS00008 MYRISTYL
N-myristoylation site

Number of matches: 4

1	19-24	GCGFCG
2	276-281	GGLHCK
3	373-378	GGMNGI
4	377-382	GIYEAI

[7] PDOC00009 PS00009 AMIDATION
Amidation site

338-341 KGKK

[8] PDOC00359 PS00375 UDPGT
UDP-glycosyltransferases signature

354-397 WIPQNDLLGHPKTKAFITHGGMNGIYEAIYHGVPVMGVPIFGDQ

[9] PDOC00804 PS01047 HMA
Heavy-metal-associated domain

12-41 LLQLFCVCGFCGKVLVWPCDMSHWLNVKV

Membrane spanning structure and domains:

Helix	Begin	End	Score	Certainty
1	5	25	1.802	Certain
2	157	177	0.765	Putative
3	181	201	0.779	Putative
4	377	397	0.735	Putative
5	491	511	1.931	Certain

5/17

BLAST Alignment to Top Hit:

```

>CRA|147000022596013 /altid=gi|10438148 /def=dbj|BAB15179.1|
      (AK025587) unnamed protein product [Homo sapiens]
      /org=Homo sapiens /taxon=9606 /dataset=nraa /length=449
      Length = 449

Score = 931 bits (2381), Expect = 0.0
Identities = 448/449 (99%), Positives = 448/449 (99%)

Query: 79  MPQDRTEENEIFVDLALNVLPGSLTWQSVIKLNDFFVEIRGLKMMCESFIYNQTLMKKL 138
      MPQDRTEENEIFVDLALNVLPGSLTWQSVIKLNDFFVEIRGLKMMCESFIYNQTLMKKL
Sbjct: 1  MPQDRTEENEIFVDLALNVLPGSLTWQSVIKLNDFFVEIRGLKMMCESFIYNQTLMKKL 60

Query: 139 QETNYDVMLIDPVI PCGDLMAELLAVPFVLT LRISVGGNMERS CGKLPAPLSYVPVPMTG 198
      QETNYDVMLIDPVI PCGDLMAELLAVPFVLT LRISVGGNMERS CGKLPAPLSYVPVPMTG
Sbjct: 61 QETNYDVMLIDPVI PCGDLMAELLAVPFVLT LRISVGGNMERS CGKLPAPLSYVPVPMTG 120

Query: 199 LTDRMTFLERVKNSMLSVLFHFWDYD YHFWEEFYSKALGRPTTLCETVGKAEIWLIRT 258
      LTDRMTFLERVKNSMLSVLFHFWDYD YHFWEEFYSKALGRPTTLCETVGKAEIWLIRT
Sbjct: 121 LTDRMTFLERVKNSMLSVLFHFWDYD YHFWEEFYSKALGRPTTLCETVGKAEIWLIRT 180

Query: 259 YWDFEFPQPYQPNFEFVGGLHCKPAKALPKEMENFVQSSGEDGIVVFSLSLGFQNVTEEK 318
      YWDFEFPQPYQPNFEFVGGLHCKPAKALPKEMENFVQSSGEDGIVVFSLSLGFQNVTEEK
Sbjct: 181 YWDFEFPQPYQPNFEFVGGLHCKPAKALPKEMENFVQSSGEDGIVVFSLSLGFQNVTEEK 240

Query: 319 ANIIASALAQIPQKVLWRYKGKKPSTLGANTRLYDWIPQNDLLGHPKTKAFITHGGMNGI 378
      ANIIASALAQIPQKVLWRYKGKKPSTLGANTRLYDWIPQNDLLGHPKTKAFITHGGMNGI
Sbjct: 241 ANIIASALAQIPQKVLWRYKGKKPSTLGANTRLYDWIPQNDLLGHPKTKAFITHGGMNGI 300

Query: 379 YEAIYHGVPMVGVP IFGDQLDNIAHMKAKGA AVEINFKTMTSEDLLRALRTVITDSSYKE 438
      YEAIYHGVPMVGVP IFGDQLDNIAHMKAKGA AVEINFKTMTSEDLLRALRTVITDSSYKE
Sbjct: 301 YEAIYHGVPMVGVP IFGDQLDNIAHMKAKGA AVEINFKTMTSEDLLRALRTVITDSSYKE 360

Query: 439 NAMRLSRIHHDQPVKPLDRAVFWIEFVMRHKGAKHLRSA AHDLTWFQHYSIDVIGFLLTC 498
      NAMRLSRIHHDQPVKPLDRAVFWIEFVMRHKGAKHLRSA AHDLTWFQHYSIDVIGFLL C
Sbjct: 361 NAMRLSRIHHDQPVKPLDRAVFWIEFVMRHKGAKHLRSA AHDLTWFQHYSIDVIGFLLAC 420

Query: 499 VATAIFLFTKCF LFSCQKF NKRKIEKRE 527 (residues 79-527 of SEQ ID NO:2)
      VATAIFLFTKCF LFSCQKF NKRKIEKRE
Sbjct: 421 VATAIFLFTKCF LFSCQKF NKRKIEKRE 449 (SEQ ID NO:4)

>CRA|1000682322899 /altid=gi|5802604 /def=gb|AAD51732.1| (AF175221)
      UDP glucuronosyltransferase UGT2A3 [Cavia porcellus]
      /org=Cavia porcellus /taxon=10141 /dataset=nraa
      /length=530
      Length = 530

Score = 795 bits (2030), Expect = 0.0
Identities = 377/530 (71%), Positives = 435/530 (81%), Gaps = 3/530 (0%)

Query: 1  MRSDKSALVFLLLQLFCVGCFCGKVLVWPCDMSHWLNVK VILEELIVRGHEVTVLTHSK 60
      M K A LLL L C G GFCGKVLVWPC+MSHWLN+K +LEEL+ RGHEVTVLIT S
Sbjct: 1  MAPGKLASAVLLLLCCAGSGFCGKVLVWPCMSHWLNLKTLLEELVKGHEVTVLTLN 60

Query: 61  PSLIDYRKPSALKFEVVHMPQDRTEENEI---FVDLALNVLPGSLTWQSVIKLNDFFVEI 117
      IDY + A FEV+ +P D+ I F++LA+NV+P + WQS L FEV+I
Sbjct: 61  NLFDYNRHPAFNFEVIPVPTDKNMSENILNEFIELAVNVMPMTPLWQSGKLLQQFFVQI 120

Query: 118 RGLTKMMCESFIYNQTLMKKLQETNYDVMLIDPVI PCGDLMAELLAVPFVLT LRISVGGN 177
      L + C + +YNQ+LMKKL+++ YDV++ DPVPCG+L+AE+L VPFV L+ S+G
Sbjct: 121 TEDLGLNCRNTVYNSLMKKLRDSKYDVLVTD PVI PCGELVAEMLGVPFVNMLKFSMGHT 180

```

FIGURE 2, page 3 of 4

6/17

Query: 178 MERSCGKLPAPLSYVPVPM TGLTDRMTFLERVKNSMLSVLFHFWIQDYDYHFWEEFY SKA 237
 +E+ CG+LPAP SYVPVP+ GLT RMTF+ERVKN + SVLF FWIQ YDY FW++FYS+A
 Sbjct: 181 IEKYCQQLPAPPSYVPVPLGGLTTRMTFMERVKNMVFSVLFDFWIIQQYDYKFWDDQFYSEA 240

Query: 238 LGRPTTLCETVGKAEIWLIRTYWDFEFPQPYQPNFEFVGGLHCKPAKALPKEMENFVQSS 297
 LGRPTTLC E+GKAEIWLIRTYWDFEFP+PY PNFEFVGGLHCKPAK LPKEME FVQSS
 Sbjct: 241 LGRPTTLC EIMGKAEIWLIRTYWDFEFP RPYPNFEFVGGLHCKPAKPLPKEME EFVQSS 300

Query: 298 GEDGIVVFSLSL FQNVTEEKANIIASALAQIPQKVLWRYKGKKPSTLGANTRYLDWIPQ 357
 GEDG+VVFSLGS+ +N+TEEKAN+IASALAQIPQKVLWRYKGKKP+TLG NTRL+DWIPQ
 Sbjct: 301 GEDGVVVFSLGSMVKNLTEEKANLIASALAQIPQKVLWRYKGKKPATLGPNTRLFDWIPQ 360

Query: 358 NDLLGHPKTKAFITHGGMNGIYEAIYHGVPVMGVPIFGDQLDNIAHMKAKGA AVEINFKT 417
 NDLLGHPKTKAFITHGG NGIYEAIYHGVPVMVG+PIF DQ DN+A MKAKGA AVE+N T
 Sbjct: 361 NDLLGHPKTKAFITHGGSNGIYEAIYHGVPVMGMPIFSDQPDNLAGMKAKGA AVEVNMNT 420

Query: 418 MTSEDLLRALRTVITDSSYKENAMRLSRIHHDQPVKPLDRAVFWIEFVMRHKGAKHLRSA 477
 MTS DLL ALRTVI D +YKENAM+LSRIHHDQPVKPLDRA FW+EFVM HKGAKHLR A
 Sbjct: 421 MTSADLLGALRTVINDPTYKENAMKLSRIHHDQPVKPLDRAAFWVEFVMHHKGAKHLRVA 480

Query: 478 AHDLTWFQHYSIDVIGFLLTCVATAIFLFTKCF LFSQCKFNKTRKIEKRE 527 (residues 1-527
 of SEQ ID NO:2)
 AHDL+WFQ++S+DVIGFLL CVA+AI L TKC LFS Q F K K K+E
 Sbjct: 481 AHDLSWFQYHSLDVIGFLLACVASAILLVTKCLFSFQNF IKGKRIKKE 530 (SEQ ID NO:5)

Hammer search results (Pfam):

Model	Description	Score	E-value	N
PF00201	UDP-glucuronosyl and UDP-glucosyl transferas	962.0	1.5e-285	1

Parsed for domains:

Model	Domain	seq-f	seq-t	hmm-f	hmm-t	score	E-value
PF00201	1/1	24	525 ..	1	507 []	962.0	1.5e-285

7/17

```

1 TTCTAGAGGG TTGGAACAAC TTTTCCCTGA TACATTGCAT TTTTTTGATA
51 CCTTCAGTAC ATGTTTAACT GGCAACCACC AGTGAACTTT ACTCTTAAAA
101 TATTAATTTT TAACTTCTGT GCTTATATTG TCATTTCAAC TCCTTGCTTA
151 GTAACTACAA AACCATTTGA GATCAGTGTG TGAGGGAAC GCCATCATGA
201 GGTCTGACAA GTCAGCTTTG GTATTTCTGC TCCTGCAGCT CTTCTGTGTT
251 GGCTGTGGAT TCTGTGGGAA AGTCCTGGTG TGGCCCTGTG ACATGAGCCA
301 TTGGCTTAAT GTCAGGTCA TTCTAGAAGA GCTCATAGTG AGAGGCCATG
351 AGGTAACAGT ATTGACTCAC TCAAAGCCTT CGTTAATTGA CTACAGGAAG
401 CCTTCTGCAT TGAAATTTGA GGTGGTCCAT ATGCCACAGG ACAGAACAGA
451 AGAAATGAA ATATTTGTTG ACCTAGCTCT GAATGTCTTG CCAGGCTTAT
501 CAACCTGGCA ATCAGTTATA AAATTAAATG ATTTTTTTGT TGAAATAAGA
551 GGAACCTTTAA AAATGATGTG TGAGAGCTTT ATCTACAATC AGACACTTAT
601 GAAGAAGCTA CAGGAAACCA ACTACGATGT AACGCTTATA GACCCTGTGA
651 TTCCCGTGG AGACCTGATG GCTGAGTTGC TTCCAGTCCC TTTGTGCTC
701 AACTTAGAA CTTCTCTAAG AGGCAATATG GAGCGAAGCT GTGGGAACT
751 TCCAGCTCCA CTTTCTATG TACCTGTGCC TATGACAGGA CTAACAGACA
801 GAATGACCTT TCTGGAAAGA GTAAAAAATT CAATGCTTTC AGTTTTGTTC
851 CACTTCTGGA TTCAGGATTA CGACTATCAT TTTTGGGAAG AGTTTTATAG
901 TAAGGCATTA GGTAAAGACAC TTTTGTTTTA TTTTAAATTT AGTTATCAAA
951 AGAAATATTT TTAATAATTG TCATACATTG TCTATGACAT ATATATGCAG
1001 GTCATAGAGT TTTTITAGAA AATGTTGTAG CTGTTTTTCA TAAAGAAAGT
1051 GTATTTGTTC TAAGCGTAAG ATAACCTACT TTCTTAATAC CAGTAATATA
1101 CTTAAAAATG ATCATCAATA ACTAAGAGAT TATATTTTGT ATTTCTCCA
1151 AATAGCGCAA ATCAACATCA CATATTTTTG AGAATCACTG ATTGTTAGTC
1201 TGAATGTTAT AGAATTTCTA TTGAAATAAA ATGCTAATCA TTATTTTCTC
1251 TCTCATCATG TATTTAAGAA AATCTTCAGA AGGTCTTCTT TGAATTAAAT
1301 TTTCAAGAGT CATTAATATG AACATTTTCT AGAATCTTTT AATTTCTTAG
1351 GTGATTACTT CACAAAAACT TGAAAAAATA TTATAAAAAG TTAATAAACT
1401 TACGGTCTTG TGGGGCATAA GATAGTAGAA TTTTACTTTT ACTGATATAC
1451 ACCTATTTGA CTTATTTTTA TTTCTTTGCT TTACTGATAA AAAGTTGTTT
1501 TGCTTTGCAA TTTTCATATA GTTGTGATCA GAGCTGGTCA ATGCAAGACA
1551 TGTTTTTATC CAAATATGTT TGAGAATTAT GTAGAAACAT GAAAAAAGGT
1601 ACAATTATAT CCGACACTAA AATATTGTTT AATGTATTCC AACGAATTCT
1651 TATGCATAGA CTGTTTCACA GAACTAATAT TCAGAGGATC CCAGTTCAAA
1701 TGTCTTAGC CTTAGACATG ATTTGAATTT ACATATATTG ATTTGCTTTA
1751 AATAATTTTC CATTCAGTAA GCTGTGCCTA GCTGCAGATA GCCTACCAGG
1801 CTTTATGGAT CTAGGTAAAC AATACAAATC TCTTGCCCTC AAGTCTACAT
1851 TCAGATATTA ATTTAAAGGG GTACAGCTAT ATAGAGGTCA CTGGCAAATT
1901 TTGGTAAAT AGGATTATAG TAAAAGCCCC CTGACAAGAT TGAAATTTAA
1951 AATAAAACAA AAGTGTATC AAAGGGGTGA AAGAGCATT TCCAATAAAC
2001 AAAAGTGGGT TCTGGCCATG CATTCAGAAA TTCCCAACA ATTCTTTAAA
2051 AATCATGGAG CAGCTTGATA TATAAGAAAT TCATTTAATA ACTATATTTA
2101 TTATGTAGCT CCAACTTACT AAATTATTGA TTATTATATA TTTTATAGAA
2151 TTATCTATTG TGAGTCTAAA TCAAGAGTAT ATATTCAAAC AACTATAGGA
2201 AAAGGGATAT CAGTCAATTT CAATTCAAGG ATTTATTTCC ATAAGTGCTT
2251 ACGCACAGGT GTATTTCAAT TTATTATACA TTGCTTTATT GTCCTTCACA
2301 AAAATTGCAA TTTACAAATT AAAGGTTTTT GAAAACCTTG AATCAAGCTA
2351 ATCAATTTGG CGTAATATTT CCAACAACAA GTGTGTACTT TTGACTCTAT
2401 CACATATTGG CATTTATCAT GCTTTTTCAA ATTTTTCATT GTTATATCTG
2451 TTACGGTGAT CTGGGATCAG TGTTCCTTGA TGGTTACACG TTTATTAGCT
2501 TGGGGGCACC TTGATGTGTT ACAATATAAG ACAGCAAAC TAAATTATAA
2551 TGTGTGTCAT GTACTAATG CTCCGCTGAT TCGTTTCCCC ATCCCACTTC
2601 TTCTTAGGCC TCCCTATTCC CTGAGACACA GTAATATAAC ATACAATGAC
2651 TTCTAAATGT TCCAGTGAAA AGAAAAGTAG CAGGTCTCTC AATTTAAACC
2701 AAAAAATATA AGGAATAAGT TTAATGAGTA CTATAGTTTA GATATGGTTT
2751 GCTTGACCTT ACAAAATCCT GTGTTGAAAT TTGATCACC AATATTGAGG
2801 TGGGGCTTGA TGGGAAGTGT TAGGGTCATG AGGGTAGATT CCTTATGAGT
2851 ACATTAATGC TCTCCCTGGG GAAATGGGTG AGTTCGTTCT CACTCTATTA
2901 GGTCCCAGGA GAGATAATTA TTAATAAGAG CCAGGAACAT CCACCTTCTT
2951 TCTCTTGAT ATCTCTCAT ATCTGATCCC TGCCTTGCT GGCTCCCAAC
3001 ATCTTCTTCA ATGAGTGGAG GAAACCAGAG GTCTTCACCA GACACAGATG
3051 TTGGTGCCAT GCCTCTTGTA TACCCTGAAG AATTGTGAGC CAAATAAAAA
3101 CCTTTTTCTT TTACAAATTA GACAGCCTCA GTTATTCCTT TGTAAGCAACA
3151 AAAAAAGCCT GGGACAGGCC AAAAATAACA CCATTGCACC AAACAGTTAA

```

FIGURE 3, page 1 of 11

8/17

```

3201 ACAAGATGTG AGTGCAAAGG AAAAGTTTTT GGAGGAAATT AAAAGTGCTA
3251 CTCCAGTGTA CATACAAATG ATAAGAACAA ATAACCATTA TCAGTGCTGA
3301 TATGGAGAAA ATTTTAGTTG TCTGGAGAGA AAATCAAATT AGCTAGCCAG
3351 CTGCAGTGAT TCATATCTGT AATCCCAGTA ACTTGGGAGG CTCAGGTGGG
3401 AGAACGGCTT GAGCCCAGAA GTTTGAAGTC CAAGGCTGCA GTGAGCTATG
3451 ATTGCTCCAC TGCACTCCAA CCTAGGTGAT AGAGCAAAAC CACTACCAA
3501 AAAAAAAAAA AAAAAAGAA GAAAAAGAAA AGAAAAAAA TAAACCAAC
3551 CACAACATCA CCTTAGGTTT TGGCATTAGC TAAAAACTAA TACATAGTAA
3601 AGCGTTAACT ATTCATTTGC ATGAAACCTC AGAGAGGAGA GGAAGATGCA
3651 AAAAAAAGA CTGAAGCTAG TAGAGGTTGA CTAATGAGGT TTACAGGAAT
3701 AAATGCGCTA CATGATGCAA AAGTTCAATG TGAAGCAATA GGAAGTCATG
3751 CAGAAGACTT AGCTAATATA CTCAGTAAAT GTGGCTACAG TAAACAAATG
3801 ATTTTCAATG TAGACCTAAC AGCCTTCTGT TGGAGAAGA TGCCATTTAA
3851 AACTTTCATA GCTAGAGAAG AGAAGTCAAT GCTTGTCTCT GAAGCTACAA
3901 AAAACAGGCT GAATCTCTTG TAGTGGCTAA TGCAGCTGAT GACAAAGGTA
3951 AAGCCAATGC CCATTTACTT TTTGTAATAA TTATAGAGGA CTCTTAATAA
4001 TTATGTTAAA TCTACTTTGC CTGTGTTATA TCAATGGAAC AACAAAGCCT
4051 GGATGATATC ACATTGGTAT ATGACATGGC TTATTGAATA TTTTAAGCAC
4101 ACTGTTGAGA CCTATTGCTC AAAAAAGAGG ATTCCTTTCA AAATATTGCT
4151 GCTCATTGAC AATTACATG GTCAACAAAG GGCTCTGATT AAGATGTACA
4201 GATATTAATG TTTGCCTGCT TGCTATTATT ACATCCATCT TACATGCCAT
4251 GGATCATATA GCCTTGACTT TCAAGTCTTA TGTAAGAAAT ATATTTTGTA
4301 AGGCTATAGC TCTTACTAAT GGGGAAAGTA TATTGAAAC CTTTTCAAAA
4351 GGATTTTTC TCTAGATTC CATTAAGAAC ATTCATGGTT CATGAGAGGA
4401 AGTCAAGATA TTAACATTAA CAAGAGTTTG GAAAAAATTT GATTCTAACT
4451 CTCCTGGATG ATTTTGAGGG ATTGAAGACA TCATGTGAAG AATTAAGTGG
4501 GGATGGGGTG GTCATGAAAA AATAAATAGA ATTATAAGTG GGCTGGAAGG
4551 TTTGCTTAAA TTGCTATAAT ATCATGATAA AACTAAAACC TGTAAAACCG
4601 GTGAGGAGGT GCTTTTAAA CAGTTACTTT TTATAGATGA ACACAGAAAT
4651 TGGTTTTGTG AGTTGGAATC TTCTCCGAGT GAAATGCTA TGAACATTGT
4701 TGAAATGGCT ACAAATGACT TAGAATATTA CACAAAATTA GTAGATAAGG
4751 CAGCATCAAG GTTTGAGAGA ATGGACTCAA ATTTTGAAAG AAATTCTACT
4801 ATGGGTAAAC TGCTGTGAAA CATCATATA TGCTACAGAG AAATCTTTCA
4851 TGAAAAGATG AGTCAATTCA TGCAACAATC TTTGTTGTCT AATTTTAAAA
4901 ATGTGCCAGC TGCCCTGATC AATCAACAGT AATCAGCACT GAGGCAAGAC
4951 CCTACACCAG AAAAAATAAA AATAAAAAAC CTCACTTGCT GAAGACTCAG
5001 CTTATTATTA GCACTTTTTA GCCATACTTT TAACTAAGGT ATGTGCATTC
5051 CTTTTTAAAC GTGATGATAT TGCACAGCTA ATAGCCTACA AGGTATGGTT
5101 AACATAACTT TTATATGTCC TGGGACCCAA ATTTGTGTGA ATCACTTTAT
5151 TGACATATTC CTTTTATTGA GATGAAGTGC AACTTATCTT GCAATATCTC
5201 CAAGATATGT GTGTATGGCA TTTCAAATAA GATGTGAAAT TATTTTATTA
5251 GTATAAAAAG CAAATTTAAT TTTCTTTCTT TTGATCATCT TTATCCTTGT
5301 TACTGTGTAT TTATCCTTTA AACATTGAAT GACTCCAATT GTTTAAACT
5351 GAGTCTTTCT TAAATGAGTC CTAATATCAT AGTAATTAAA ATCACCTACA
5401 AGTTGGTAAT GCAGGCAGCA TGTGAGGCAC AGAAAACAAC AAATTTATAA
5451 GACATAAATG CATTTGCTTG GAAGCTGAGA GAAGGCTCTA TTCTAATTTT
5501 TGATAACTTC AAAGTGAAGT TCTTCAGTAA AATTTATTCA CTATCAAATT
5551 CAAGGCGTTT GGATTTATGA CCTAGGAAAA AACTTCAAAC ATTAATAATG
5601 GATGACCTTA AAAAGAGGCT CTCCACACTA TGGTGTATAA CACCACCAAC
5651 TTTGATTAGA ATTTTAAAGA GAAACAAATT CTCTTATGGA GTTTATCTTT
5701 TTATCACTTG CAAAATATGT TTTTGTAAG AGATACTAAT TACTTAGTTA
5751 TTTGTAGTTA GCCATTCTTC TGATTAAAAA CCTAAAATTA AATCTTGAAA
5801 ATGTGTTTTT CTTCAAAACA CATCATTTGA GAGAAACACT AAAGTAAGTG
5851 TATGATTATC ATAGCATGTA CATAGGTGCT TCACAACCCA AAAAGAATAT
5901 TGTATGGGTT AAGAATCAGT AAAGGAATTT CTCCTAATAA AACAGTAGCC
5951 TATTAATTAA AGTAATGATA TGCAATACAG CAAGTTAAAG GGAAGTATC
6001 CTGGTGGGAT TATTGAAAGA TATACCCTTG ACTATAGATT AGAAAAATACA
6051 GAGATGTTAT TTAGTGAAGA TATTGTGGTA CTCATTTATC ATCTGCAATT
6101 CACTTGACAG GAAAAAATG AGTAATAAAT TCATTTGCAT TTTGGATTTG
6151 TGTCTTTAAG TTGTGAAAA ACACTTAAAT ATAACCATCT GTCCCTTGCT
6201 CTTCCCTTCC TTCCTTCTTT CTTCCCTTCC TTCCTTCTTT CCATCCTTCC
6251 CTCCCTCCAT CCTTCCCTTCC TTCCTTCTTT CTTCCCTTCC TTTCTTCTC
6301 TGTCTTCTCT TCTTTTCTCC TTTCTTCTTT TTTCTTCTTT TATTATTTCA
6351 TTAATCCCCC CTTCCATTG ACGTCTAAAA GCCATGTTGT TCTAGAGGAC

```

FIGURE 3, page 2 of 11

9/17

```

6401 TTAAACTTAT TTTTTCCTTA ATAGCTTACT GAAAAATTAG TGATACAATT
6451 TTTTATTTGA ATTGTATGCT AATTCATTCT GTTATTTCTT TTATTGAGGA
6501 AGGCCCACTA CATTATGTGA GACTGTGGGA AAAGCTGAGA TATGGCTAAT
6551 ACGAACATAT TGGGATTTTG AATTCCTCA ACCATACCAA CCTAACTTTG
6601 AGTTTGTGG AGGATTGCAC TGTAACCTG CCAAAGCTTT GCCTAAGGTA
6651 GGACTATTGT ATTAAGGAAT ATTATGTACT TTATGACATG ACTTGTTTTC
6701 CCTTGAAAGA TTACAACCTT AGTTATAGAA GGATGATGTT GAATGTCGTC
6751 TGTTTGACGC TCCATATTTA TTTTCCATGC CACAGGGGCT CTTATAGGTG
6801 ATTATATGTC TTTTCGGTAT TATATTGAGA AAGTAGGCAG AAGAATTTCA
6851 TGATTAGAAT AGATTTTAAA ATACTAGTAT TACAATAGTT TGGATAATAA
6901 ATTGAATTAA TAGGGAATTG GAGCCATGAA GATCACTAAA AAGAATGCTC
6951 TAGCCTTTCT CACAATCAAA TTGGGCTTAT GAACAAGGAT ATTTGTTCATG
7001 ATAGTACAGA AATAAGCATA TTTTCATGAG ACATATTGGA TATATCCAC
7051 AGGAGTTGGT GAGTGAGAGA AAATAAGTGA TGAAGGAAGA CAAAGAATAA
7101 AAGAAAAATT CAATAAATGG AAAGTTAAG TGTTTAATGA TAGTGATGAC
7151 TTTTACTCAA ATAAGTGCTT AGAAGTCATC TTGTTTGTA TTTATATGAT
7201 GAATTCTGTG TTGTGACTAT CCACTTTGAG CTCGTGAGAA TGTTAGGTGA
7251 GGTTTAATAA AAGCCATTG AGAAAAACAA GGTTCACACC TCTGTGGACA
7301 GAAATCTAAA TATCGATAGT TATCAGGACA AAGTAGAGCT CATAGAATAA
7351 ATTTTGACGC CTGCAGGTTT GTTTTGAGT GAAAAATAAA TTGTATACTA
7401 TATTCCTAAA TCATCAGAGG AAAAAATTTA TAGTTCAAGG AATGTTGAAA
7451 GAAACAATAT TGAGAAGTAA AAGTGAGTAA TAGTTGTTAT AGTTTTTTAA
7501 TAGTTTTGTA AGTATGCTT GAGTTCCTG TCCCAAAGT GGCTATTAGC
7551 TTAGCCTTG ACCTGACAAG GTTCTAGGAT ATTTAGTCAT GGATGTTTAT
7601 AATCTACCTC TTACGGGATA CTTTTTATTC TGATGAACAG CCTAATGCCT
7651 AAGTGTGCAA TCTATACCAA GATTGTTCTT ATAGGGAAGT TGTTTACACT
7701 GGAAGACACC ACTGTGCTC TTGTATGACC TATGTCTTCT TTATCCCTAC
7751 AAAGGTAACC ACATTATAGG AAACCCTGAC AAGGCCAGAT GTTATATTTG
7801 TGTTGGTCAA GTGAGAAAAC ATGGGAGAAA CTTAACCAA CACATAAAAT
7851 AACAGAAACA GTCTTCTTTG ACCATTTCTA GAGAAAAGAG TTCAGCATCC
7901 CTTGTAAGGC CACTAGGAAG AAGAAAATTC TCTGGGAAAA GCACATTCOA
7951 CCAATGAATG GAGACCAAGA AAGAGAGTGA GGGATCTATG TGCCAAAATG
8001 TTAAGTGGG TCCAGGGTGT TACCTAGGTG GGTTCCTAAT GGGGAAGTGT
8051 AATTGGTAGG TTTAATGCAA GCAGGCACAA AGTCCATGGA GGCATTCTGA
8101 GACTGAAAGA TAGTCACCTT GGCATATCTG CACAGAATCT GATCAGTGAT
8151 TCAAGCCCAA GTAGGCTGTA TCTAGTTGTC CTATAGGGTG GTTACCAGGA
8201 GGCAGTGTGT AAGTAAAAAT CCTGACTGAA CACATTGAGG AAATGGAAGG
8251 AGGTGGAAGA TTTTAAACGG TGTCAGTGTG GACTAAGACC TGCTTCTGGT
8301 ATGGAAAATT CAACTTATAT TTTAAATGCA TAGCCAGACA ACATAAAAT
8351 ATAAGAATTT ACCACAATAG CTATGGTAAC AATACTGGGT TTACCTATTA
8401 CTACAGAGTG AAAAGAAAAC CCTCATTTC CATTTTATGG AAATATAATC
8451 AAAATCCTAT AAGGAAGGTT TCAGAGCCAG TAGGATTTCC AGAAAAATTA
8501 TTGGTTTTAT AGTAAGATGT GTATTGATGA ATATAATTTT ATTTATTAAT
8551 TATTAATATC ACTTTACTTA CCAGGAAAGT TATACCAGAA AACCAGCTC
8601 TCTTAAGCCA TGGCATCTGT ATCTAAAATA GAAATACAGA AGGAGAGCTG
8651 ACAATTTCCA TCATTCTCTA GGTAACTCC CATGCCATTC TACCCTTTAT
8701 TCCCACATC CCAGTTTAC ACACACACAC AAACACACAC ACACAAACAC
8751 ACACTCATAG AAATAATCAT AGAAGACATA TTTTAAAAA AGTTAGATCC
8801 ATACAGTAAT AATTTATTAG GTAAAAGCTT TTGTGCTGAT AATTTTACAA
8851 GTTTAATTGA GATATATTTT AGGGCTGTCT TACACTAAAT ATTTATTTT
8901 ATTTTTTAAA TTTGACATGT AATAATTGCA CATGTTTAAG AGAAATGCTG
8951 TGGTATTACA ATACATTTAA ATGTTGTGTA ATAATTACAT CAAGATAATA
9001 AACCCATCAT CTAATATTT ATCATTCTCT TGTGGTGATA ACATTCAAAA
9051 ACCTCCTTTC TGGCTATCTT GAAATATGTA ATACATTACT ATTAACATA
9101 GTTACCCAAC AACTTAATAT AATAACAGAA CATATTCTTC CAAATTTAAA
9151 CGTTGTATCC ATTGATCCAC CATTTCTCAT TGCCCTCCCT ACTATCTT
9201 CAGCCTCTAG TAACCACAAT TCTACTCTCT AATTATATTA TGAATGCATT
9251 TTTTGATTCC ACATATAAGG GATACCATGC TATCTCTGCC TGGATTATTT
9301 CAGTTAACAT TATGCCCTGG AGGTTTCTAC ATGTTTCTAC AAATGACAGG
9351 ATTTTCATTCT TTTTTCCTCA ATATATATTT AATGAAATGG ATATATATAA
9401 ACATTGGAAA ATGTATATAT ATATATATAT CTCCAGTGGA ATGCTATTGA
9451 GCTATAAAAA AGTTAATATA TAATAGAAAT AAAGCTTATA TATATCTAAT
9501 GGAATGGATA TATATATATA ATGGAATAGA AATATATATC TATACATATA
9551 AACACACGCA ATATACATAT CCATTTCATT GCATATATAT ATATATAGAG

```

FIGURE 3, page 3 of 11

10/17

```

9601 AGAGAGAGAG AGAGATATTT TCAATGTGT GTATATATAT CCAATGGAAT
9651 GGACATATAT ATATGTATAT TTTTCCATA TTTTCTTTAT GTATTTCTTC
9701 ATTAATGGAT GTTTAGGTTG ATTCATCCCT TGGGTATATG AATAATGTTG
9751 ATGTAACAT AGAAGGACAG ATATCTCTAT GACTTCTTAG TTTATTTAAA
9801 TATACACCCA GTAATGGAAA TGCTGTATAA TATGGTAGTT CTATTTTCAT
9851 TTTTGGAGGA ACTACCATAC CGTTTTCCTT ACTAATGTA CTAATTTGCA
9901 TTTCCCTCAA CAGTTTATAA AAGATCTTCT TTCTCTGCAT ACTTTCTAGC
9951 ACTTGTTATT TTTGCCTTTT GATAATAGCC ATAACAGGGG TGATGTGATA
10001 TCTCATTGTA GTTTTGATTT GCATTTCCCT GATGATTAGT GATTTTGAGC
10051 ATTTTGTAAT TATACTTCTT AGTCACTGAT AGTCTTCTTT TGAGAAGTGT
10101 CTATTCAGGT CTTTGTCTTA TTTTAAATC AAATTAGTAA TTTATTTTAA
10151 TTGACTGATG TGACTTCTAT GTATATTTGA GATAGTAACT TATTGTCAGA
10201 TTCATAGTTT GCAATATATT TTCATGTTGT GAATGTCTC TTCACCTGT
10251 TGTTTGCTTC ATTTTCTCTG CACAAGCTCA ATGCTTTGAT ATAACCCATT
10301 TATCTACTTT TCCTTTTGTG GGCTGTGCTT CTGAAGTCTT ATCCAAAAAA
10351 ATCCTTGCCCT AGACCAATGT CACAATCAT TCCTCCTACA GTTTCTTCTA
10401 GTAGTTGTAT AATGTTTGCC CTTATATTTA ACTTTGTAAT TCATTTTAC
10451 TTACTTTGTA TATGGTGAGG GATAGAGGTC TAGTTTCATT TTCTGCATGT
10501 GGATATGCAG TTTTCCTAGC ACCATTTAGT GAAGAGGTTG CCTTTTCTCT
10551 ATTATGTGTT CTTGGCACCT TTGTCAAAAG TCAGTTAGCT GCTATATTC
10601 TCCATTTGTG TTGTTATAGA GGAACACATG AGACTAGCAA ATTTATATAT
10651 CAAATAGAAT TATTTGAATG ATAGTTCTGC ATACTGTACA AGAAGCACAG
10701 CACTGACTTC TGCTTGGCCT CTGGTAAGGT TCTCAAGATG CTTCCACTTG
10751 TGGTAGAAGG CAAACATGAG CTGGTATATG CAAAGTCTC ATGACAAGAG
10801 AGGAAACCAT AAAGAGGGGA TGTGAGGGAG TGCCAGGTTT TGTAACAACA
10851 CTAGCTCTTC TGGGAACATA TAGAGTAAAA ATTGCGCTCC CAGGCAGGGG
10901 ATTAATCTAT TCATGAGGGA TCTGCTTCCA TGACAAAGGC ACATTCGTGT
10951 AGATTCTACC CCAATATTG GGGATCAAAT TTTAACATGA AGTGTGGAGG
11001 GCTCAAATAT CCATACTATG GCAGCAGTAA ATGCATAAAT TTATTTTGTG
11051 GATCTCTATT CTATATAGTA TTGGTGATG TATCTGTTTT CATGCCACTG
11101 CCATACTGTT TTGGTGATGA TATCTATGCT ATATATGTGT GTGTGTATAT
11151 ATATATTATA TATATGTATA TATGTGTATA TTATATATAT GTATATATGT
11201 GTATATTATA TATATATAAT ACTTTAAGTT TTATATATAT ATAAAAACT
11251 TTAAGTTCAA GGGTACATGT GCAGGATGTG CAGGTCAGTT ACATAGGTAT
11301 ACATGTGCCA TTTTGGTTTG CTGCATGCAT CAACTCATCA TTACATTAGG
11351 TATTTCTCCT AATGCTATCC CTCCACCAGC CACCCAACCC CCAACAGGCC
11401 AGGTGTGTGA TGTTCCCCGC CCTGTGTCCA TGTGTTCTCA TTGTTCACTT
11451 CCTACCTAAA AGTGAGAACA TGCAGTGTTT GATTTTCTAT CCTTGTGATA
11501 GTTTGCTGAG AATGACTGTT TTCAGCTTCA TCCATGTCCC TCAAAAGGAC
11551 ATGAACFCAT CCTTATTTAT GGCTGCATAG TATTCATGG TGTATATGTG
11601 CTACGTTTTT TTAATCCAGT CTATCACTGT TGGACATTTG GGTGGTTCC
11651 AAGTCTTTCG TATTGTGAAT AGTGCTACAA TAACCATATG TGTGCATGTG
11701 TCTTTATAGC AACATGATTT ACTATCCTTT GTGTACATAC CCAGTAATGG
11751 GATAACTGGG TCAATGGTA TTTCTAGTTC TAGATCCTTG AGGAATCCCC
11801 ACACTGTCTT CCACAATGGT TGAACATAAT TACATTCCCA CCAACAGTGT
11851 AAAAACGTTT CTATTTCCCC ACATCCTCTC CAGTATCTGT TGTTTCTGA
11901 CTTTTTAATG ATGGCCATTG TAACACATAT GAGATGGTAT CTCATTGTGG
11951 TTTTGTGTTG CATTTCTCTG ATGACCAGTG ATGATGAGCA TTTTTCATG
12001 TGTCTTTTGG CTGCATAAAT GTCTTCTTTT GACAAGTGTC TGTTCATATC
12051 CTTTGCCCACT TTTTCAATGG AGTTGTTTGT TTTTTCCTG TAAATTTGTT
12101 TAAGTTTCAAT GTAGATTCTG GATATTAGCC CTTTGTGAGA TGGGTAGATT
12151 GCAAAAATTT TCTCCCATTC TGTAGGTTGC CTGTTCAACC TGATGGTAGT
12201 TTCTTTTGCT GTGCAGAAGC TCTTTAGCTT AATTAGATCC CATTTGTCAA
12251 TTTCCGCTTT TGTTGCCATT GCTTTTGGTG TTTTAGTCAT GAAACCCCTG
12301 CCCAGGCCTA AGTCTCAGT GGTATAGCCT AGGTTTCTT CTAGGATTTT
12351 TATGGTTTCA GGTCTAACAT TTAAGTCTTT AATCCATCTT AAATTAATTT
12401 TTGTATAAGA TGTAAGAAGG GATCCGTTTC AACTTTCTAC ATATGGCTAG
12451 CGTGTGTTCC CAACACCATT TATTAAATAG GGAATCCTTT CTCCATTCT
12501 TGATTTTGTC ATATTTGTCA AACATCACAT GGTAGAGAT GTGTAGTGT
12551 ATCACTGAGG CCTCTTTTCT GACTCCATTG ATCTATATAT CTGTTTGTG
12601 ACCAATACCA TGTGTTTTC GTTACTGCAA CCTGTGAATG CAATTTGACA
12651 TTCAGGACCA TGATGCCTCC AGTCTCTTTT TTTTTCCTA AATAATTTT
12701 TTGTCAATGT AAGCTCATTT TCGCTTCTTT CTGATCCATA AAGTATTTT
12751 TTCCCATTTT GTGGAGAACG CCGCNNNNNN NNNNNNNNNN NNNNNNNNNN

```

FIGURE 3, page 4 of 11

11/17

```

12801 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNGGCACA CCTCGTGCGC
12851 ATATATATAT ATATATATAT ATATACCTCT ATATATATAT ACATACATAC
12901 ATACATACAC ACCTCCTTGT CTGGTGTGGG ATCAGGGTAA TGCTAGCCTC
12951 ACAAGATGAT ACTGAAGTGT TTTTGCCTTT TTGACTTTTT GATGGTTTGG
13001 AAGAGTGAGA AAAAGTGTTA TTAATTATTC TTTAAATTTT GTTGAATTC
13051 ATAGTGAAGA CCTTAGCTCA CTGGCTTTTT TAATGAGAAC TTTATTACTG
13101 ATTTAACTT CTTCTTCATT ATTTATTTCT GCCTTGTTTT TATTTCTTCA
13151 TAATCCAGTC CTATTTTATG TGTCCACTAA ATTGTTTATT TTCCTAGAAT
13201 TTTTCCATTT ATTGGCATAT GCATGTCCAT AGAAGCCTTT TATAGTCCTT
13251 TTCAATTTCTA GTGTCATTTT TTTCTTTTTT TTTAAGAATC CTTAAGATTT
13301 TAGAGATGAA ATGTCACTTT GTTACGCATA CTGGAGTGGC GTGACATTAT
13351 TATAGCTCAC TGAACCCAA ACTCCTGAGT TTAAGCAATC CTTCTACCTC
13401 AAAATTCCAA AATTCCTGAG TAGCTGAGAC AGGCATACAC CATCAAGACT
13451 GGCTAATTTA TTTCAAATTT TGTAGAGATG GGTTCCTACT AAGCTATTCT
13501 CAATCTTTGG GCTTCAAGTG ATTCTTCAGC CTCTGTCTCT GAAAATGCTG
13551 GGTTTATAGA TATGAGCCTC TATGCCTGAT TTGCTTTGTC TCTTTGTAAT
13601 CTCCCATTTT ATTTGTGTCT TTTCTGGTTT GTTTCATTTT GTTATGTTTT
13651 CAGTTACCTT GCTAAAGCTT TGTCGATTTT ATCTCTTCAA ACAACTAACT
13701 CAATATTTTG CTGATTTTCC ATATAGTATT TTATTTCTAT TTCATTATTT
13751 TCTGCTCTAA TCTTTGTTAA ATATCTTGTT TTCCTAATAA TTTTGAGTTT
13801 CTTGTTCCTT GTTTTCTAAT TCCTTGCGAT GTTATCATAA ATTGTTTATT
13851 TGATATCTTT CTACTTTTTT GATGTGTGTG TTCGTGTGTG TAGACTTTCC
13901 TCTTTATTAT TCTGATTTCT TCCTCAATTC TCTAATATTA TGATTGCATT
13951 ATTTTCCAAAG TTTCTTTTGT TTTTATTTAT ATAGTTTATG TGATTCTCTGA
14001 ACTGTGCAAA GAGATTATTG TGAATTTGAT GTCGGATATT TAAGCATTTT
14051 CAAAACCTTT GGTGCATTAT TGAAATTTTA TTGGTTTATT TTAGAGATGT
14101 CATACTTCCC AGTTTTTTTT TAACAATACT TGCTCTTTAT ATTGATGTCT
14151 ACATATTTAA AAAGATAACC ACCTGATTCA GCTTTTAAAG GTGATATGCA
14201 GTGGTGTTAA GTGTGTACTG CTTAATATCA GAGCTGAATC ACTGCCCTGA
14251 GGATTCTTTC TGTCTGAGG AGAGCTTGTA GTTAATAGCA GAACCTAAAT
14301 AGTGCAGTAG AGCTAAATCT CTTCCATGCT GTTGTTTTCC TGTCTGGGGA
14351 AGACTTATCA TGACCATGAA AACATAATGC TGTGCCAGAA CTTAAACCCA
14401 AACCTGTAGT AATTTCTGAG TTGAGGAAGG CTTAAGAAAT AACTGGAAC
14451 TAGTTACTAA CCTGATAGTT GTTCTGAGT CAGAGAAATG CTCTGCATGA
14501 TCACCTGGGA TATTTGTAAA ATCTAACCAA AGATTCTAGC CTTCCCCTTG
14551 GATTGTGCCT CCTGTACTAC TGTAGTGCTG GCTAGGTCTT CATCAGTGAA
14601 TTCCCTGCTG ATAGGACCAC AAAGCATCTG CCAAGATCTG TTTGCCATTT
14651 GCTGTGATTA GTGCTTCTGC TCTTGCTTC CAATTCAACT CAGGTGGTTC
14701 AGCCCTTCTG ACACTCCTAA TACCTCCTGT GGGATGGAAC ATAGAAGGCT
14751 TCTCACAATG ATTACACAC TGATATGGAG ATTGAATGTC CAGTTGCAAC
14801 TATTTTCTTC CACCTGTGTA ATTCAGGTA CAGGGAAGTT TTCTGTGACT
14851 GATGCTATTT TGGTTTGGAG AATGGGGTGA TGTGGCACA TGATCTTTCT
14901 TCTTTCTGGT CATGGATTTT TTAATTTCCA TGAACCCATA AGATTTTCA
14951 CTTTTCTTCT GAGCTCTGGT GCTTTCAGAG TGGTATTTTT ATATTCGAAT
15001 AGTTGCTAGT TGTACTTTTA AAAGCGATTG ATGCTGGAGG TCTTCTATTC
15051 CACCATCTCG CTGATGTCAG TCCTCAAATA ATAATTTTAT ATTTTAGCAA
15101 ATTATTTTGG TTTTAGGATT TTGTGTCTAC GTGACACAGA CATGAAAAGA
15151 GATGTACTCA TTAAGTAAAC TTTTGCATA CTGTTTTGGT TGTGCGCCTT
15201 TTCTAGTATG AATGATTACA TATTTAAGCC ACATGTTTTA TACATAGACT
15251 GTCCTTTAAA GAGACTAGAT AGTTCTGTGT GTCAGCATAT AGGGACAGAA
15301 TATAACTACA CATTAATAAT TTCTCAAGTA TTTATTTTAG AAGTGAAGT
15351 AACCTTTATT TTAATTTTGG TTATATTATG CCTCTGTAAT GCAGATAAAT
15401 TTTTATCTTC AGGAAATGGA AAATTTTGTG CAGAGTTCAG GGAAGATGG
15451 TATTGTGTGT TTTTCTCTGG GGTCACTGTT TCAAATGTT ACAGAAGAAA
15501 AGGCTAATAT CATTTGCTCA GCCCTTGCCC AGATCCCACA GAAGGTCAGT
15551 AAAACCTCCA ATCCTGATAA GCAGCTATTC ACATAATGAA ACAGTATGGT
15601 TTTATTTGGG TCTTGAATCT CATTTTCCAC TTAGCATAAC AGGTACCAAA
15651 ATTTGCAAAA CATTATAGTA GTGTACATGG GCATAACTGA TCATTTGCCT
15701 ACTGAGTCTT GCTGTACTG GAAACAACCT TCTTGATTGT CATTGTGTTA
15751 TAATAAAATA GATATAATAA ATAAAGCTCT ACCTTATATT TTAGGATTTG
15801 AAATCTAAAA CGGTGTGCCA ATGATTCCAA AAAAAAATTC TGACATCTAT
15851 TATTTCAAAG GACCAGAAAA AGGAAAACTG ATATAAAAAA AAAAGAAGA
15901 ATCAATCTCA AGAATATCTT CTATATTTG TGTGTATAAA AACTGTATTC
15951 AGGGTAGTTT TGCTTAGAAA TAAAAGCTCA GATTAATGTA GTCTTTCTAA

```

FIGURE 3, page 5 of 11

12/17

```

16001 ATAATTAGAA GTTCAAAAAG TAAAATGTCA ATTACAATTA TAGTATAGTA
16051 ACAATTATTT AAGTAATGTA ATTATTTATG ATACTCCACT AATTTTAACT
16101 TTATTATTAC TGTAAATTCTA GAATTTCAACA CTTTAGATAG TGCTATATAT
16151 AAACATATCCA AAAGATATTT CATTTTATAT TTAGCTAAAA TACTTCAAAC
16201 TCAATAAAGG CAAGCATACT AATTAGGAAT TTGAAATATT GTAATTTCAA
16251 TTATGAAATT ATCTGTTAAG TAGTTTGAAA CATCTATGCC GTTCTTTGTT
16301 TTCAAATGTA TAAAAATTTGT ATAGGTGTCC AACAAAGAAA AATTGTGTAA
16351 AAAAAAGGTA CAATCTCAAA GAAAATTTAT CATTGAACAG TGGACATAA
16401 GTAATTTTCT AGCTCATTCT TCTCAATAA AACAAATTA TATAAGAAGA
16451 AAGAGGCCAG GAAGGAAATA GAGAAGAAAA GACACCCGAT TATCCAAAAG
16501 ACACACATAA TTGAAAGCAA ATTTTATCT GCAGGGAAC GTAAATTTGA
16551 TGGTAGAATG AGATTGGCTC CATGAGTTAA AATGACACAC AGATCAGGTA
16601 CTTATAAAAT TTTTAATTCT TATATAAAAA TAGATTAGCC ACTGCTGAAT
16651 TATTTTTTTA AATATTCCT GGTATTCTCA TTCTCAAATA TTTTAAATG
16701 TAAATAAAAT AATAATAGCA TACCTAATAG GCAACTGGTA CACATTATTT
16751 TAAAAGATCT TTGTAACACG TCCTACTATA TCTTTCAGTC TTTACGCGGT
16801 AGCTCTACAC ACCCCTGTCT CAACCATCAC CTGAAGTACA ATGAGTTTAT
16851 AATTTATAAC TATATCTACA TCCTTAGAAT GCTAATATCC TGTGGTTTAC
16901 TCTGTGAAAT ACATGTGTTT CTCCGTAGG TGTATGGAG GTACAAAGGA
16951 AAAAAACCAT CCACATTAGG AGCCAATACT CGGNNNNNNN NNNNNNNNNN
17001 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNAAAAAAA
17051 AAGACCAAT CCCAAAGAAA ATTTATCATA GAACAATGGA ACATAGGTAA
17101 TTCTCTAGCT CATTCGTCTT CAATAAAACA AATAAATATA AGAAGACAAA
17151 GGTCAAGGAG GAAATAGAGA AGAAAAGATA ACCGATTATC CAAAATCACA
17201 CACAAAATTG AAAGCAAATT TTATCTGTGG GGAAGTGTAA ATTTGATGGT
17251 AGAACCAGAA TAGTCCATG ATTTGAAATG ACACAGAGAT CATGTACTTA
17301 TAAAAATATT TATTCTTATA AGAAAATTGA GTAGCCAGTG CTGAATTACT
17351 TTTTAATGAT TCACTGATAT TCTCATACTC AGATATTTTA ATTGATATTA
17401 AAATAATAAT AGTATACTTA ATAGTCAACT GGTACACATT ATTTGAAAGG
17451 ACTTTTGTA AAGTCCCTAC TATGTCTTTT ACTGTTTACA CAGTACCTCT
17501 ACATACCCCT GTCTCAACCA ACACCTGAAG TACAATGAGT TTATAATTTA
17551 TAACTATATC TACATCCTTA GAGTGCTAAT ATCCTGTGGT TCAATCTGTG
17601 AAATACATGT GTTCTTCCA TAGGTGTTAT AGAGATACAA TGGAAAAAAA
17651 ACCATCCACA TTAGGAACCA ATACTCGGCT GTATGATGGG ATACCCCAAG
17701 ATGATCTTCT TGGTAGGTCT ATGAGAAAGT AAAAATATGA ACTAGACGAG
17751 GAAAAAATGA ATAAATGTTA AACAGCAAGC AAATTCAGCA AAGATCTAAA
17801 ATTATAAAAC TTTATTTTAC TTACTCTTTT GAAGCAGATA TAATTAAAGG
17851 ATTGACTAAA ATTGTATAGA TTCACACTTT CTATTGTTAA GGTGAGAGTG
17901 ACAGGAAATT CAGAAGGAAT TAATGCCTAT TTTTCTGGAG ATAGAAATGA
17951 TCTTTAGTAG CAATGCTCCA TGTGCTCACC TTCTAAAGAA AGTGCTGTAC
18001 GCTTCAGTGA GTTATCTCGT AATTCCCATC TGAGTTTTTT AAATAATTTT
18051 AAAAGTTTAG AATAAAATAT CTCACCATTT CTCATCCAAT TTACATACTA
18101 GGTCACTCCA AAACCAAGC TTTTATCACT CATGGTGGAA TGAATGGGAT
18151 CTATGAAGCT ATTTACCATG GGGTCCCTAT GGTGGGAGTT CCCATATTTG
18201 GTGATCAGCT TGATAACATA GCTCACATGA AGGCCAAAGG AGCAGCTGTA
18251 GAAATAAACT TCAAACTAT GACAAGCGAA GATTTACTGA GGGCTTTGAG
18301 AACAGTCATT ACCGATTCCT CGTAAGTACT ACTGCTTGTA CAGACTGATC
18351 TAACATTGAC TATGTTATAC ATTATACCAG AAAATGTTAA ATATCATCCT
18401 GGTAGACATG TTGAGGGATT TTAATCCACA ATATTGAGTC ATTCATCACC
18451 TTGTTACTGG AATAGTTGTG GAAATGTTAG TTCATAGAGT GTCAAACCTT
18501 CTTTATGGAA ATATTAGGTT TAAGTTAACA ACTGGCTTAC TAAGCTTTTA
18551 TTCACATCTT AATTTTACCC CATTTTGTTA AGAATATACT CTTTCAGTCT
18601 CTCCACTATA TCTGTTAAT ACTATGTAAC CAACAATATT CATGTCACAA
18651 CCAGATCAAA TCTTTTACTG AACATGTCT TGGCTTGCA TACATATACT
18701 ACGGTTTATC TACGTGCTT TTATGAAAC AAAACTACAA CTTTCTAAGT
18751 TCTATGTGTG TTTTCCCTT CCAGTTATAA AGAGAATGCT ATGAGATTAT
18801 CAAGAATTCA CCATGATCAA CCTGTAAAGC CCCTAGATCG AGCAGTCTTC
18851 TGGATCGAGT TTGTCTATG CCACAAAGGA GCCAAGCACC TGGATCAGC
18901 TGCCCATGAC CTCACCTGGT TCCAGCACTA CTCTATAGAT GTGATTGGGT
18951 TCCCTGCTGAC CTGTGTGGCA ACTGCTATAT TCTTGTTCAC AAAATGTTTT
19001 TTATTTTCTT CTCAAAAATT TAATAAAACT AGAAAGATAG AAAAGAGGGA
19051 ATAGATCTTT CCAAAATCAA GAAAGACCTG ATGGGGTAAT CCTGTTAATT
19101 CCAGCCACAT AGAATTGGT GAAAACCTTG CTATTTTCAT ATATCTATT
19151 CTGTTATTTT ATCTTAGCTA TATAGCCTAG AATTCCACGA TCATGAGGTT

```

FIGURE 3, page 6 of 11

13/17

```

19201 GTGAGTATAT CTCATTCTTT CGTTGTATTT TCCTAGGTGT CTTTACTCTC
19251 TTCTCTCACT TTGTGACACA AGGACATGAA TACATCTAAA TTTTCCTATT
19301 TCTGATATGA CTGTTTTGAT GATGTCATTA CTTCTATAAC CTTAAGTGAT
19351 AGGGTGACAT GCAATATGAT TATTCCTGGT GTGCGCCCAA ACACATGGAT
19401 ATAAAGAGGT AAAAACTTA AAATTCACAA AATTCAGTAA ACCACACAAA
19451 TCAGGTAAGT GTTCTATGAG ATTAGCTGGC TATGAGAAAC ATAATGATGT
19501 TTCTTTTTCA ATTTAAATAA GCCCTTCTAC ATAGCCAGCA TCAGTGATCT
19551 CAGAAAATAA ATTGCTAATA ATGATGACAT GGCATTATGC TTAGAAAAGT
19601 TTGCTGTATT TCCATAGACC TCATCTAGAT GTCATGGCCT ACATTTCTGC
19651 CATCACTCAA CCAATACTTT TTTCTGTTTT CTTGATGATA AAAAGACCTT
19701 TCTCATGATT GCCATCAAAT AACAAAAGAA ACTATTTTTT TTCTCACATA
19751 GAGAACATGT CAGTAAGATA TTCAAGGTGA ACAGATATTT TTGGGATTAG
19801 TAACTATTTG AATATATGTG TGATAATTAC TGAGTTTATA AAATTTATTT
19851 GATAGTACAC TTAAGAAGA TTTATATGTT TATTCTTTAA AAATGATGAA
19901 TACTCATAAT TCTTATCTCT ATAATCAAAA GTATAATTTA CTGTAGAAAA
19951 ATAAAGAGAT GCTTGTCTG AAAGTAAGAT CAGTGAAGT CTTTTCAGTC
20001 TCAATCTTTG AGAATTGTAA ATTCATCAAA TAATTGCTTA CATAGTAAAA
20051 ATTTAAGGTA TTAGAAAACC TGCATAACAA ATAGTATTAT ATATTAAATA
20101 TTTTGATATG TAAAGCTCTA CACAAAGCTA AATATAGTGT AATAATGTTT
20151 ACATGATATA GCAAATATGT TAATCTTCTC ATTTTTTTTAC TGTCATATAA
20201 TCTTAGTGAT ATGCCTATTA ATAGTTTTAA ATAAATAAAT TGGCTTATCT
20251 GGCTTTTGA AAATTTTGAA ATTCTTACAG ATGTTGATTA GGTATATCTA
20301 CAAATTAATT TCAATTTTAA AATGATGATA TAAAAATAAA TATAAGTATT
20351 TTTCTTGTGT ATGTATACAA TAAATATAAA TAAATTTGTT TACTGTTTTG
20401 AAAGTTTCTT AAGTTTTTAC ACTGATATGT TTTTGTGACTT TTACAATATT
20451 ATTATAATCT AGGAAAAGCT GATTATATCT GTTTTAAGCC TCATCTTTTC
20501 TCTGTAATTA AACACAGTAA TTTATTAACA TGCTGTGACA GGTGGGAAGC
20551 CATTTCTGGA GTTGAGCCTG CTGACACTCT GGAGCTTTTT AGGTTGGACG
20601 TTCATTGTAT GTGGGACTCT CTGCCTCTCG ATAGCTGTTG CTCATAAGAC
20651 TCTCCTTCAT CAATCTGGCA TTGAATTTTG CGATCAGTTG CAATCAGAAT
20701 CCAATTGGCC TTGCCGTTT AGTATGTTCT ATCCTAACCA GCAATTCTTA
20751 ACCAGGAGCC TGCCCAGGTT TGTTCGTCT TCCCTGTAAG AAGCTCCCAG
20801 CATAAATATT CTAAATTTTA CACTACTAAT CTATTAACCA ACCTTTGGAC
20851 CATGTTCACT TTAGGTTGAG CATAGTGTGA TGAGATGCAA ATTAAATTAC
20901 AATCCTATAG GTGTGTGTTA TAAATTTTAA AGTGATATAA TTAAATAACA
20951 CATTCTAAGT ATCCAACAAA GGTCAAAAAA ATGATATAAA GTCACCAAAC

```

(SEQ ID NO:3)

FEATURES:

```

Start: 197
Exon: 197-911
Intron: 912-6498
Exon: 6499-6647
Intron: 6648-15412
Exon: 15413-15544
Intron: 15545-16929
Exon: 16930-16940
Intron: 16941-17632
Exon: 17633-17712
Intron: 17713-18101
Exon: 18102-18321
Intron: 18322-18774
Exon: 18775-19051
Stop: 19052

```

CHROMOSOME MAP POSITION:

Chromosome 4

ALLELIC VARIANTS (SNPs):

Position	Major	Minor	Domain
1735	A	G	Intron
1922	A	G	Intron

14/17

2361	C	T	Intron
7371	G	C	Intron
9558	G	A	Intron
10579	T	G A	Intron
10625	C	T	Intron
11147	A	G	Intron
15131	C	T G	Intron
15221	A	G T	Intron
15778	T	C	Intron
15895	-	A	Intron
19786	-	T	Beyond ORF(3')
20157	G	A	Beyond ORF(3')
20246	T	C	Beyond ORF(3')
20681	C	A	Beyond ORF(3')
20819	T	C	Beyond ORF(3')

Context:

DNA

Position

1735 TACTTTACTGATATACACCTATTGACTTATTTTATTTCTTTGCTTTACTGATAAAAAG
TTGTTTGGCTTTGCAATTTTCATATAGTTGTGATCAGAGCTGGTCAATGCAAGACATGTT
TTTATCCAAATATGTTTGAGAAATATGTAGAAACATGAAAAAGGTACAATTATATCCGA
CACTAAAATATGTTTAAATGTATTCCAACGAATTCTTATGCATAGACTGTTTCACAGAAC
TAATATTGAGAGGATCCAGTTCAAATGTCTTAGCCTTAGACATGATTGAATTTACAT
[A, G]
TATTGATTTGCTTTAAATAATTTCCATTGAGTAAAGCTGTGCCTAGCTGCAGATAGCCTA
CCAGGCTTTATGGATCTAGGTAAACAATACAAATCTCTGGCCTCAAGTCTACATTCAGA
TATTAATTTAAAGGGGTACAGCTATATAGAGGTCACTGGCAAATTTGGTAAATAGGAT
TATAGTAAAAGCCCCCTGACAAGATTGAAATTTAAATAAAAACAAAAGTGTATCAAAGG
GGTGAAAGAGCATTTTCCAATAAAACAAAAGTGGGTCTGGCCATGCATTGAGAAATCCC

1922 ATATTGTTTAAATGTATTCCAACGAATTCTTATGCATAGACTGTTTCACAGAACTAATATT
CAGAGGATCCAGTTCAAATGTCTTAGCCTTAGACATGATTGAATTTACATATATTGA
TTTGCTTTAAATAATTTCCATTGAGTAAAGCTGTGCCTAGCTGCAGATAGCCTACCAGGC
TTTATGGATCTAGGTAAACAATACAAATCTCTGGCCTCAAGTCTACATTCAGATATTAA
TTTAAAGGGGTACAGCTATATAGAGGTCACTGGCAAATTTGGTAAATAGGATTATAGT
[A, G]
AAAGCCCCCTGACAAGATTGAAATTTAAATAAAAACAAAAGTGTATCAAAGGGGTGAAA
GAGCATTTTCCAATAAAACAAAAGTGGGTCTGGCCATGCATTGAGAAATCCCCAACAAT
TCTTTAAAAATCATGGAGCAGCTTGATATATAAGAAATTCATTTAATAACTATATTTATT
ATGTAGCTCCAACCTTACTAAATTTATTGATTATTATATATTTTATAGAATTATCTATTG
AGTCTAAATCAAGAGTATATATTCAAACAACATATAGGAAAAGGATATCAGTCAATTTCA

2361 CAGCTTGATATATAAGAAATTCATTTAATAACTATATTTATTATGTAGCTCCAACCTACT
AAATTATTGATTATTATATATTTTATAGAATTATCTATTGTGAGTCTAAATCAAGAGTAT
ATATTCAAACAACATAGGAAAAGGGATATCAGTCAATTTCAATTCAGGATTTATTTCC
ATAAGTGCTTACGCACAGGTGTATTTTATTTATATACATTGCTTTATTGTCCTTCACA
AAAATTGCAATTTACAAATTAAAGGTTTTTGAAAACCTTGAATCAAGCTAATCAATTTGG
[C, T]
GTAATATTTCCAACAACAAGTGTGACTTTTGGCTCTATCACATATTGGCATTATCATG
CTTTTCAAATTTTTCATTGTTATATCTGTTACGGTGATCTGGGATCAGTGTTCCTTGAT
GGTTACACGTTTATTAGCTTGGGGGCACCTTGATGTGTTACAATATAAGACAGCAAACCT
AATTATAAATGTTGTGCATGTACTAAGTCTCCGCTGATTGTTTTCCCATCCCACTTCT
TCTTAGGCCCTCCCTATTCCCTGAGACACAGTAATATAACATACAATGACTTCTAAATGTT

7371 AAATAAGTGATGAAGGAAGACAAAGAATAAAAGAAAATTTCAATAAATGGAAGTTTAA
TGTTAATGATAGTGATGACTTTTACTCAAATAAGTGCTTAGAAGTCATCTTGTGTTGTA
TTTATATGATGAATCTGTGTTGTGACTATCCACTTTGAGCTCGTGAGAATGTTAGGTGA
GGTTAATAAAAGCCATTTGAGAAAAACAAGGTTTCAACCTCTGTGGACAGAAATCTAAA
TATCGATAGTTATCAGGACAAAGTAGAGCTCATAGAAATAATTTTGAGCCTGCAGGTTT
[G, C]
TTTTGGAGTGAAAATAAAATTGTATACATATTTCCCTAAATCATCAGAGGAAAAAATTTAT
AGTTCAAGGAATGTTGAAAGAAACAATATTGAGAAGTAAAAGTGAGTAATAGTTGTTATA

FIGURE 3, page 8 of 11

15/17

GTTTTTTAATAGTTTTGTAAGTATGTCTTGAGTTCAGTGTCCCAAAAGTGGCTATTAGCT
 CTAGCCTTGACCTGACAAGGTTCTAGGATATTTAGTCATGGATGTTTACATAATCTACCTCT
 TACGGGATACTTTTTATTTCTGTATGAACAGCCTAATGCCTAAGTGTGCAATCTATACCAAG

9558 TCCACATATAAGGGATACCATGCTATCTCTGCCTGGATTATTTTTCAGTTAACATTATGCC
 TGGAGGTTTCATTTCATGTTTCTACAAATGACAGGATTTTCATTCTTTTTTTTCCAATATATA
 TTTAATGAAATGGATATATATAACATTGGAAAATGTATATATATATATATCTCCAGT
 GGAATGCTATTGAGCTATAAAAAAGTTAATATATAATAGAAATAAAGCTTATATATATCT
 AATGGAATGGATATATATATATAATGGAATAGAAATATATATCTATACATATAAACACAC
 [G, A]
 CAATATACATATCCATTTCATTGCTATATATATATATAGAGAGAGAGAGAGAGATAT
 TTTCAAATGTGTGTATATATATCCAATGGAATGGACATATATATGTATATTTTTTCCA
 TATTTTCTTTATGTATTTCTTCATTAAATGGATGTTTAGGTTGATTCATCCCTTGGGTATA
 TGAATAATGTTGATGTAAACATAGAAGGACAGATATCTCTATGACTTCTTAGTTTATTTA
 AATATACACCCAGTAATGGAATGCTGTATAATATGGTAGTTCTATTTTCATTTTTTGGAG

10579 CAATGCTTTGATATAACCCATTATCTACTTTTCTTTTGTGGCTGTGCTTCTGAAGTC
 CTATCCAAAAAATCCTTGCCCTAGACCAATGTCACAAATCATTCCCTCCTACAGTTTCTTC
 TAGTAGTTGTATAATGTTTGGCCTTATATTTAACTTTTGAATTCATTTTTTACTTACTTTG
 TATATGGTGAGGGATAGAGGTCTAGTTTCATTTTCTGCATGTGGATATGCAGTTTCTCTA
 GCACCATTTAGTGAAGAGGTTGCCTTTTTTCTATTATGTGTTCTTGGCACCTTTGTCAA
 [T, G, A]
 GTCAGTTAGCTGCTATATTCCTCCATTGTGTGTTTATAGAGAACACATGAGACTAGCA
 AATTTATATATCAAATAGAATATATTTGAATGATAGTTCTGCATACTGTACAAGAAGCACA
 GCACTGACTTCTGCTTGGCCTCTGGTAAGGTTCTCAAGATGCTTCCACTTGTGGTAGAAG
 GCAAAATGAGCTGGTATATGCAAAGGTCTCATGACAAGAGAGGAAACCATAAAGAGGGG
 ATGTGAGGGAGTGCCAGGTTTTGTAAACAACCTAGCTCTTCTGGGAACTAATAGAGTAAA

10625 GTGCTTCTGAAGTCCTATCCAAAAAATCCTTGCCCTAGACCAATGTCACAAATCATTCCCT
 CCTACAGTTTCTTCTAGTAGTTGTATAATGTTTGGCCTTATATTTAACTTTGTAATTCAT
 TTTTACTTACTTTGTATATGGTGAGGGATAGAGGTCTAGTTTTCATTTTCTGCATGTGGAT
 ATGCAGTTTTCTAGCACCATTTAGTGAAGAGGTTGCCTTTTTTCTATTATGTGTTCTTG
 GCACCTTTTGTCAAAGTCAGTTAGCTGCTATATTCCTCCATTTGTGTTGTTATAGAGGAA
 [C, T]
 ACATGAGACTAGCAAATTTATATATCAAATAGAATTATTTGAATGATAGTTCTGCATACT
 GTACAAGAAGCACAGCACTGACTTCTGCTTGGCCTCTGGTAAGGTTCTCAAGATGCTTCC
 ACTTGTGGTAGAAGGCCAAACATGAGCTGGTATATGCAAAGGTCTCATGACAAGAGAGGAA
 ACCATAAAGAGGGGATGTGAGGGAGTGCCAGGTTTTGTAAACAACCTAGCTCTTCTGGGA
 ACTAATAGAGTAAAATTCGCCTCCAGGCAGGGGATTAATCTATTCATGAGGGATCTGC

11147 ACAACTAGCTCTTCTGGGAACTAATAGAGTAAAAATTCGCCTCCAGGCAGGGGATTAAT
 CTATTCATGAGGGATCTGCTTCCATGACAAAGGCACATTCCTGTTAGATTCTACCCCAAT
 ATTGGGGATCAAATTTTAACATGAAGTGTGGAGGGCTCAAATATCCATACTATGGCAGCA
 GTAAATGCATAAATTTATTTTGTGGATCTCTATTCATATAGTATTGGTGTATGTATCTG
 TTTTCATGCCACTGCCATACTGTTTTGGTGATGATATCTATGCTATATATGTGTGTGTGT
 [A, G]
 TATATATATTATATATATGTATATATGTGTATATTATATATATGTATATATGTGTATATT
 ATATATATATAATACTTTAAGTTTTATATATATATAAAATACTTTAAGTTCAAGGGTACA
 TGTGCAGGATGTGCAGGTGCTTACATAGGTATACATGTGCCATTTTGGTTTGGTGCATG
 CATCAACTCATCATTACATTAGGTATTTCTCCTAATGCTATCCCTCCACCAGCCACCCAA
 CCCCCAACAGGCCAGGTGTGTGATGTTCCCGCCCTGTGTCCATGTGTTCTCATTGTTC

15131 CAGGGAAGTTTTCTGTGACTGATGCTATTTTGGTTTGGAGAATGGGGTGTGTGGCACA
 TGATCTTTCTTCTTCTGGTTCATGGATTTTTTAATTTCCATGAACCCATAAGATTTTTCA
 CTTTCTTCTGAGCTCTGGTCTTTCAGAGTGGTATTTTATATTCGAATAGTTGCTAGT
 TGTACTTTTAAAGCGATTGATGCTGGAGGTCTTCTATTCCACCATCTCGCTGATGTCAG
 TCCTCAAATAATAATTTTATATTTTAGCAAATATTTTGGTTTTAGGATTTTGTGTCTAC
 [C, T, G]
 TGACACAGACATGAAAAGAGATGTACTCATTACTGAACTTTTTGCATACTGTTTTGGTT
 GTGCGCCTTTTCTAGTATGAATGATTACATATTTAAGCCACATGTTTTATACATAGACTG
 TCCTTTAAAGAGACTAGATAGTTCTGTGTGTCAGCATATAGGGACAGAATATACTACAC
 ATTAATAATTTCTCAAGTATTTATTTTAGAAGTGTAAAGTAACCTTTATTTTAATTTTGT
 TATATTATGCCTCTGTAATGCAGATAAATTTTATCTTCAGGAAATGGAAAATTTTGTCC

FIGURE 3, page 9 of 11

16/17

- 15221 TTAATTTCCATGAACCCATAAGATTTTTCTACTTTTCTTCTGAGCTCTGGTGCTTTCAGAG
TGGTATTTTTATATTCGAATAGTTGCTAGTTGTACTTTTAAAGCGATTGATGCTGGAGG
TCTTCTATTTCCACCATCTCGCTGATGTGAGTCTCCTCAAATAATAATTTATATTTTAGCAA
ATTATTTGGTTTTAGGATTTTGTGTCTACGTGACACAGACATGAAAAGAGATGTACTCA
TTACTGAAACTTTTTGCATACTGTTTTGGTTGTGCGCCTTTCTAGTATGAATGATTACA
[A, G, T]
ATTTAAGCCCATGTTTTATACATAGACTGTCTTTAAAGAGACTAGATAGTTCTGTGTG
TCAGCATATAGGGACAGAATAAATACTACACATTAATAATTTCTCAAGTATTTATTTTGA
AGTGTAAAGTAACCTTTATTTTAAATTTTGTATATATGCCTCTGTAATGCAGATAAAT
TTTATCTTCAGGAAATGAAAATTTTGTCCAGAGTTCAGGGGAAGATGGTATTGTGGTGT
TTTCTCTGGGGTCACTGTTTCAAATGTTACAGAAGAAAAGGCTAATATCATTGCTTCAG
- 15778 GTTTCAAAATGTTACAGAAGAAAAGGCTAATATCATTGCTTCAGCCCTTGCCAGATCCC
ACAGAAGGTCAGTAAACCTCCAATCCTGATAAGCAGCTATTACATAATGAAACAGTAT
GGTTTTATTTGGGTCTTGAATCTCATTTCCTACTAGCATAACAGGTACCAAATTTGCA
AAACATTATAGTAGTGTACATGGGCATAACTGATCATTGCTTACTGAGTCTTGTCTGTTA
CTGGAAACAACCTTTCTGATTGTCATTGTTTATAATAAATAGATATAATAAATAAAGC
[T, C]
CTACCTTATATTTTAGGATTTGAAATCTAAAAGCGTGTGCCAATGATTCCAAAAAAT
TCTGACATCTATTATTTCAAAGGACCAGAAAAAGGAAACTGATATAAAAAAAGAA
GAATCAATCTCAAGAATATCTTCTCATATTTGTGTGTATAAAACTGTATTAGGGTAGT
TTTGCTTAGAAAATAAAGCTCAGATTAATGTAGTCTTTCTAAATAATTAGAAGTTTCAA
AGTAAATGTCAATTACAATTATAGTATAGTAACAATTATTTAAGTAATGTAATTATTTA
- 15895 TATGGTTTTATTTGGGTCTTGAATCTCATTTCCTACTTAGCATAACAGGTACCAAATTT
GCAAAACATTATAGTAGTGTACATGGGCATAACTGATCATTGCTTACTGAGTCTTGTCTG
TTACTGGAACAACCTTTCTTGATTGTCATTGTTTATAATAAATAGATATAATAAATAA
AGCTCTACCTTATATTTTAGGATTTGAAATCTAAAAGCGTGTGCCAATGATTCCAAAAA
AAATCTGACATCTATTATTTCAAAGGACCAGAAAAAGGAAACTGATATAAAAAA
[-, A]
GAAGAATCAATCTCAAGAATATCTTCTCATATTTGTGTGTATAAAACTGTATTAGGGT
AGTTTTGCTTAGAAAATAAAGCTCAGATTAATGTAGTCTTTCTAAATAATTAGAAGTTT
AAAAGTAAATGTCAATTACAATTATAGTATAGTAACAATTATTTAAGTAATGTAATTAT
TTATGATACTCCACTAATTTTAACTTTATTATTACTGTAATTCTAGAATTTACACTTTA
GATAGTGTATATATAAACTATCCAAAGATATTTCAATTTATATTTAGCTAAAATACTT
- 19786 GAAACATAATGATGTTTCTTTTCAATTTAAATAAGCCCTTCTACATAGCCAGCATCAGT
GATCTCAGAAAATAAATTGCTAATAATGATGACATGGCATTATGCTTAGAAAAGTTTGCT
GTATTTCCATAGACCTCATCTAGATGTCATGGCCTACATTTCTGCCATCACTCAACCAAT
ACTTTTTCTGTTTTCTTGATGATAAAAAGACCTTTCTCATGATTGCCATCAAATAACAA
AAGAACTATTTTTTTCTCACATAGAGAATGTGTCAGTAAGATATTCAAGGTGAACAGA
[-, T]
ATTTTTGGGATTAGTAACTATTTGAAATATGTGGTGATAATTACTGAGTTTATAAAATTT
ATTTGATAGTACACTTAAAGAGATTATATGTTTATTTTAAATGATGAATACTCA
TAATCTTATCTCTATAATCAAAGTATAATTTACTGTAGAAAATAAAGAGATGCTTGT
TCTGAAAGTAAGATCAGTGAAGTCTTTTCACTCTCAATCTTTGAGAATTGTAATTCAT
CAAATAATTGCTTACATAGTAAAAATTTAAGGTATTAGAAAACCTGCATAACAAATAGTA
- 20157 ACACTTAAAGAAGATTTATATGTTTATTTCTTTAAATGATGAATACTCATAATCTTAT
CTCTATAATCAAAGTATAATTTACTGTAGAAAATAAAGAGATGCTTGTCTGAAAGTA
AGATCAGTGAAGTCTTTTCACTCTCAATCTTTGAGAATTGTAATTCATCAAATAATTG
CTTACATAGTAAAAATTTAAGGTATTAGAAAACCTGCATAACAAATAGTATTATATATTA
AATATTTTGATATGTAAAGCTCTACACAAAGCTAAATATAGTGAATAATGTTTACACTA
[G, A]
TAAGCAAATATGTTAATCTTCTCATTTTTTTACTGTCTATATAATCTTAGTGATATGCCTA
TTAATGATTTTTAAATAAATAAATTTAGGCTTATCTGGCTTTTTGAAAATTTTGAATTTCTTA
CAGATGTTGATTAGGTATATCTACAAATTAATTTCAATTTTAAATGATGATATAAAT
AAATATAAGTATTTTTCTTGTGTATGTATACAATAAATATAAATAAATTTGTTTACTGTT
TTGAAAGTTTCTTAAGTTTTTACACTGATATGTTTTTGACTTTTACAATATTATTATAA
- 20246 GAAAAATAAAGAGATGCTTGTCTGAAAGTAAGATCAGTGAAGTCTTTTCACTCTCAAT
CTTTGAGAATTGTAATTCATCAAATAATTGCTTACATAGTAAAAATTTAAGGTATTAGA
AAACCTGCATAACAAATAGTATTATATATTAATATTTTGATATGTAAAGCTCTACACAA
AGCTAAATATAGTGAATAATGTTTACACTAGTAAGCAAATATGTTAATCTTCTCATTTT

FIGURE 3, page 10 of 11

17/17

TTTACTGTCATATAATCTTAGTGATATGCCTATTAATAGTTTTAAATAAAATAAATTGGCT
 [T, C]
 ATCTGGCTTTTTGAAAATTTGAAATTCCTACAGATGTTGATTAGGTATATCTACAAATT
 AATTTCAATTTTAAAATGATGATATAAAAAATAAATAAGTATTTTCTTGTGTATGTAT
 ACAATAAATAAATAAATAAATTGTTTACTGTTTGAAAGTTTCTTAAGTTTTTACACTGAT
 ATGTTTTTTGACTTTTACAATATTATTATAATCTAGGAAAAGCTGATTATATCTGTTTTA
 AGCCTCATCTTTCTCTGTAATTAACACAGTAATTTATTAACATGCTGTGACAGGTGGG

20681 TAAAATTGTTTACTGTTTGAAAGTTTCTTAAGTTTTTACACTGATATGTTTTTTGACTT
 TTACAATATTATTATAATCTAGGAAAAGCTGATTATATCTGTTTTAAGCCTCATCTTTTC
 TCTGTAATTAAACACAGTAATTTATTAACATGCTGTGACAGGTGGGAAGCCATTTCTGGA
 GTTGAGCCTGCTGACACTCTGGAGCTTTTAGGTTGGACGTTTCATTGTATGTGGGACTCT
 CTGCCTCTCGATAGCTGTGTCTATAAGACTCTCCTTCATCAATCTGGCATTGAATTTTG
 [C, A]
 GATCAGTTGCAATCAGAATCCAATTGGCCTTGCCGTTTTAGTATGTTCTATCTTAACCAG
 CAATTTCTAACCAGGAGCCTGCCAGGTTTGTCTGTCTTCCCTGTAAGAAGCTCCCAGC
 ATAAATATTCTAAATTTTACACTACTAATCTATTAAACCAACCTTTGGACCATGTTCACTT
 TAGGTTGAGCATAGTGTGATGAGATGCAAATTAATTAACATCCTATAGGTGTGTGTTAT
 AAATTTTAAAGTGATAAATTAATAACACATTCTAAGTATCCAACAAAGGTCAAAAAA

20819 AATTTATTAACATGCTGTGACAGGTGGGAAGCCATTTCTGGAGTTGAGCCTGCTGACACT
 CTGGAGCTTTTTAGGTTGGACGTTTCATTGTATGTGGGACTCTCTGCCTCTCGATAGCTGT
 TGCTCATAAGACTCTCCTTCATCAATCTGGCATTGAATTTTGCGATCAGTTGCAATCAGA
 ATCCAATTGGCCTTGCCGTTTTAGTATGTTCTATCTTAACCAGCAATTTCTAACCAGGAG
 CCTGCCAGGTTTGTCTGTCTCCCTGTAAGAAGCTCCCAGCATAAATATTCTAAATTT
 [T, C]
 ACACTACTAATCTATTAAACCAACCTTTGGACCATGTTCACTTTAGGTTGAGCATAGTGTG
 ATGAGATGCAAATTAATTACAATCCTATAGGTGTGTGTTATAAATTTTAAAGTGATATA
 ATTAATAACACATTCTAAGTATCCAACAAAGGTCAAAAAATGATATAAAGTCACCAAA
 C

SEQUENCE LISTING

<110> WEI, Ming-Hui et al.

<120> ISOLATED HUMAN DRUG-METABOLIZING
PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN
DRUG-METABOLIZING PROTEINS,
AND USES THEREOF

<130> CL000763-PCT

<140> (to be assigned)

<141> 2001-08-24

<150> 60/228893

<151> 2000-08-30

<150> 09/784340

<151> 2001-02-16

<160> 5

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2759

<212> DNA

<213> Human

<400> 1

```

caaccattgc agatcagtggt gtgaggggaac tgccatcatg aggtctgaca agtcagcttt 60
ggtatttctg ctccctgcagc tcttctgtgt tggctgtgga ttctgtggga aagtcctggt 120
gtgggcctgt gacatgagcc attggtctaa tgtcaaggtc attctagaag agctcatagt 180
gagaggccat gaggtaacag tattgactca ctcaaagcct tcgttaattg actacaggaa 240
gccttctgca ttgaaatttg aggtggtcca tatgccacag gacagaacag aagaaaatga 300
aatatttgtt gacctagctc tgaatgtctt gccaggctta tcaacctggc aatcagttat 360
aaaattaaat gatttttttg ttgaaataag aggaacttta aaaatgatgt gtgagagctt 420
tatctacaat cagacgctta tgaagaagct acaggaaacc aactacgatg taatgcttat 480
agaccctgtg attccctgtg gagacctgat ggctgagttg cttgcagtcc cttttgtgct 540
cacacttaga atttctgtag gaggcaatat ggagcgaagc tgtgggaaac ttccagctcc 600
actttcctat gtacctgtgc ctatgacagg actaacagac agaattgacct ttctggaaag 660
agtaaaaaat tcaatgcttt cagttttgtt ccacttctgg attcaggatt acgactatca 720
tttttgggaa gagttttata gtaaggcatt aggaaggccc actacattat gtgagactgt 780
gggaaaagct gagatatggc taatacgaac atattgggat tttgaatttc ctcaaccata 840
ccaacctaac tttagatttg ttggaggatt gcactgtaaa cctgccaaag ctttgcctaa 900
ggaaatggaa aattttgtcc agagttcagg ggaagatggt attgtggtgt tttctctggg 960
gtcactgttt caaatgtta cagaagaaaa ggctaataatc attgcttcag cccttgccca 1020
gatcccacag aaggtgttat ggaggtacaa aggaaaaaaa ccatccacat taggagccaa 1080
tactcggtcg tatgattgga taccacagaa tgatcttctt ggcatccca aaaccaaac 1140
ttttatcact catggtggaa tgaatgggat ctatgaagct atttaccatg gggtccttat 1200
ggtgggagtt cccatatttg gtgatcagct tgataacata gctcacatga aggccaaagg 1260
agcagctgta gaaataaact tcaaaactat gacaagcgaa gatttactga gggctttgag 1320
aacagtcatt accgattcct cttataaaga gaatgctatg agattatcaa gaattcacca 1380
tgatcaacct gtaaaagccc tagatcgagc agtcttctgg atcgagtttg tcatgcgcca 1440
caaaggagcc aagcacctgc gatcagctgc ccatgacctc acctggttcc agcactactc 1500
tatagatgtg attgggttcc tgctgacctg tgtggcaact gctatattct tgttcacaaa 1560
atgtttttta ttttctgtgc aaaaatttaa taaaactaga aagatagaaa agagggaata 1620
gatctttcca aattcaagaa agacctgatg gggtaatcct gtttaattcca gccacataga 1680
atttggtgaa aaccttgcta ttttcatatt atctattctg ttattttatc ttagctatat 1740
agcctagaat tccatgatca tgaggttgtg agtatatctc attctttcgt tgcattttcc 1800

```



```

taggtgtgct tactctcttc tctcactttg tgacacaagg acatgaatac atctaaattt 1860
tcctatttct gatatactg tttccatgac gtcattactt ctctaacctt aagtgatagg 1920
gtgacctgca atagtctgat tcctgggtgtt tgcacaaaaca catggatgta aagaagtaaa 1980
aaatgtaaaa ttcacaaaat tcagtaaaacc acacaaaatca atgaagcatt ctatgacatt 2040
agcttgttat gagtaacata atgatttttc tttttcaatt taaataagcc cttctacata 2100
cccagcatta ctgatctcag acaatgaatt gctaaaaatg acgatagggc attacactca 2160
gaatagtttg ctatatttcc acatacctca tctagatgtc atagcctaca tttctgccat 2220
cacttaactg acatTTTTTg tgtgttcttg atgataaata gacagttctt attattgtcc 2280
tcaaataata aaagaaactg aaattttctt acatagagaa aatgtccata agatattcaa 2340
gttaaacaga ttattttgag ataagtaacc attagaaata tgtgattgta atttctgatt 2400
ttataaaaatt ttaattgata gtacacttga tttaaatgtc tattctttaa aatgatgaat 2460
actcataatt cttatctcta taatcaaaag tataatttac tgtagaaaaa taaagagatg 2520
cttgttctga aagtaaaaaa aaaaaaaaaa aaaacactgt catgccgtta cgtagcgtat 2580
cgttgacagc ccactgtcat gccgttacgt agcatatcgt tgacagcgac actgtcatgc 2640
cgttacgtag cgtatcgttg acagcactgt catgcgttac gagcgtatcg ttgacagcac 2700
tgtcatgccg ttacgtagcg tatcgttgac agcaaaacac tgtcagccgt tacgtagcg 2759

```

<210> 2

<211> 527

<212> PRT

<213> Human

<400> 2

```

Met Arg Ser Asp Lys Ser Ala Leu Val Phe Leu Leu Leu Gln Leu Phe
1          5          10          15
Cys Val Gly Cys Gly Phe Cys Gly Lys Val Leu Val Trp Pro Cys Asp
20          25          30
Met Ser His Trp Leu Asn Val Lys Val Ile Leu Glu Glu Leu Ile Val
35          40          45
Arg Gly His Glu Val Thr Val Leu Thr His Ser Lys Pro Ser Leu Ile
50          55          60
Asp Tyr Arg Lys Pro Ser Ala Leu Lys Phe Glu Val Val His Met Pro
65          70          75          80
Gln Asp Arg Thr Glu Asn Glu Ile Phe Val Asp Leu Ala Leu Asn
85          90          95
Val Leu Pro Gly Leu Ser Thr Trp Gln Ser Val Ile Lys Leu Asn Asp
100         105         110
Phe Phe Val Glu Ile Arg Gly Thr Leu Lys Met Met Cys Glu Ser Phe
115         120         125
Ile Tyr Asn Gln Thr Leu Met Lys Lys Leu Gln Glu Thr Asn Tyr Asp
130         135         140
Val Met Leu Ile Asp Pro Val Ile Pro Cys Gly Asp Leu Met Ala Glu
145         150         155         160
Leu Leu Ala Val Pro Phe Val Leu Thr Leu Arg Ile Ser Val Gly Gly
165         170         175
Asn Met Glu Arg Ser Cys Gly Lys Leu Pro Ala Pro Leu Ser Tyr Val
180         185         190
Pro Val Pro Met Thr Gly Leu Thr Asp Arg Met Thr Phe Leu Glu Arg
195         200         205
Val Lys Asn Ser Met Leu Ser Val Leu Phe His Phe Trp Ile Gln Asp
210         215         220
Tyr Asp Tyr His Phe Trp Glu Glu Phe Tyr Ser Lys Ala Leu Gly Arg
225         230         235         240
Pro Thr Thr Leu Cys Glu Thr Val Gly Lys Ala Glu Ile Trp Leu Ile
245         250         255
Arg Thr Tyr Trp Asp Phe Glu Phe Pro Gln Pro Tyr Gln Pro Asn Phe
260         265         270
Glu Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Ala Leu Pro Lys
275         280         285
Glu Met Glu Asn Phe Val Gln Ser Ser Gly Glu Asp Gly Ile Val Val
290         295         300

```

Phe Ser Leu Gly Ser Leu Phe Gln Asn Val Thr Glu Glu Lys Ala Asn
 305 310 315 320
 Ile Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val Leu Trp Arg
 325 330 335
 Tyr Lys Gly Lys Lys Pro Ser Thr Leu Gly Ala Asn Thr Arg Leu Tyr
 340 345 350
 Asp Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr Lys Ala
 355 360 365
 Phe Ile Thr His Gly Gly Met Asn Gly Ile Tyr Glu Ala Ile Tyr His
 370 375 380
 Gly Val Pro Met Val Gly Val Pro Ile Phe Gly Asp Gln Leu Asp Asn
 385 390 395 400
 Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Glu Ile Asn Phe Lys
 405 410 415
 Thr Met Thr Ser Glu Asp Leu Leu Arg Ala Leu Arg Thr Val Ile Thr
 420 425 430
 Asp Ser Ser Tyr Lys Glu Asn Ala Met Arg Leu Ser Arg Ile His His
 435 440 445
 Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile Glu Phe
 450 455 460
 Val Met Arg His Lys Gly Ala Lys His Leu Arg Ser Ala Ala His Asp
 465 470 475 480
 Leu Thr Trp Phe Gln His Tyr Ser Ile Asp Val Ile Gly Phe Leu Leu
 485 490 495
 Thr Cys Val Ala Thr Ala Ile Phe Leu Phe Thr Lys Cys Phe Leu Phe
 500 505 510
 Ser Cys Gln Lys Phe Asn Lys Thr Arg Lys Ile Glu Lys Arg Glu
 515 520 525

<210> 3

<211> 21000

<212> DNA

<213> Human

<220>

<221> misc_feature

<222> (1)...(21000)

<223> n = A,T,C or G

<400> 3

ttctagaggg ttggaacaac ttttccctga tacattgcat ttttttgata ccttcagtag 60
 atgttaaaact ggcaaccacc agtgaacttt actcttataaa tattaatttt taacttctgt 120
 gcttatattg tcatttcaac tccttgctta gtaactacaa aaccattgca gatcagtgtg 180
 tgagggaact gccatcatga ggtctgacaa gtcagctttg gtatttctgc tcctgcagct 240
 cttctgtgtt ggctgtggat tctgtgggaa agtcctgggtg tggccctgtg acatgagcca 300
 ttggcttaat gtcaaggcca ttctagaaga gtcatagtg agaggccatg aggtaacagt 360
 attgactcac tcaaagcctt cgtaattga ctacaggaag ccttctgcat tgaaatttga 420
 ggtggtccat atgccacagg acagaacaga agaaaatgaa atatttgttg acctagctct 480
 gaatgtcttg ccaggcttat caacctggca atcagttata aaattaaatg atttttttgt 540
 tgaaataaga ggaactttta aaatgatgtg tgagagcttt atctacaatc agacacttat 600
 gaagaagcta caggaaacca actacgatgt aacgcttata gaccctgtga ttccccgtgg 660
 agacctgatg gctgagttgc ttccagtcoc ttttgtgctc acacttagaa cttctctaag 720
 aggcaatatg gagcgaagct gtgggaaact tccagctcca ctttccatg tacctgtgcc 780
 tatgacagga ctaacagaca gaatgacctt tctggaaaga gtaaaaaatt caatgctttc 840
 agttttgttc cacttctgga ttcaggatta cgactatcat ttttggaag agttttatag 900
 taaggcatta ggtaagacac ttttgtttta tttttaattt agttatcaaa agaaatattt 960
 ttaaaaaattg tcatacattg tctatgacat atatatgcag gtcaatgagt ttttttagaa 1020
 aatgtttag ctgtttttca taaagaaagt gtatttgttc taagcgtaag ataacctact 1080
 ttcttaatac cagtaataata cttaaaaatg atcatcaata actaagagat tataattttgt 1140
 atttctcca aatagcgcaa atcaacatca catatttttg agaactcactg attgttagtc 1200

tgaatgttat	agaatcttcta	ttgaaataaa	atgctaataca	ttatcttctc	tctcatcatg	1260
tatttaagaa	aatcttcaga	aggtcttctt	tgaattaatt	tttcaagagt	cattaaattg	1320
aacatcttct	agaattcttt	aatttcttag	gtgattactt	cacaaaaact	tgaaaaata	1380
ttataaaaag	ttaaaaaact	tacggctctg	tggggcataa	gatagtagaa	tttttacttt	1440
actgatatac	acctatattga	cttattttta	tttctttgct	ttactgataa	aaagttgttt	1500
tgctttgcaa	ttttcatata	gttgatgatca	gagctgggtca	atgcaagaca	tgtttttatc	1560
caaatatggt	tgagaattat	gtagaaacat	gaaaaaagg	acaattatat	ccgacactaa	1620
aatattgttt	aatgtattcc	aacgaattct	tatgcataga	ctgtttcaca	gaactaatat	1680
tcagaggatc	ccagttcaaa	tgtccttagc	cttagacatg	atgtgaattt	acatatattg	1740
atgtgcttta	aataatcttc	cattcagtaa	gctgtgccta	gctgcagata	gcctaccagg	1800
ctttatggat	ctaggtaaac	aatacaaatc	tcttggcctc	aagtctacat	tcagatatta	1860
atttaaaggg	gtacagctat	atagaggtca	ctggcaaatt	ttggtaaaat	aggattatag	1920
taaaagcccc	ctgacaagat	tgaatattaa	aataaaacaa	aagtgttatc	aaaggggtga	1980
aagagcattt	tccaataaac	aaaagtgggt	tctggccatg	cattcagaaa	ttccccaca	2040
attctttaaa	aatcatggag	cagcttgata	tataagaaa	tcatttaata	actatattta	2100
ttatgtagct	ccaacttact	aaattattga	ttattatata	ttttatagaa	ttatctattg	2160
tgagtctaaa	tcaagagtat	atattcaaac	aactatagga	aaagggatat	cagtcaattt	2220
caattcaagg	atttatttcc	ataagtgtct	acgcacaggt	gtatttcatt	ttattataca	2280
ttgctttatt	gtccttcaca	aaaattgcaa	tttacaattt	aaaggttttt	gaaaaccttg	2340
aatcaagcta	atcaatttgg	cgtaatatct	ccaacaacaa	gtgtgtactt	ttgactctat	2400
cacatattgg	catttatcat	gctttttcaa	atttttcatt	gttatatctg	ttacgggtgat	2460
ctgggatcag	tgttccttga	tggttacacg	tttatttagct	tgggggcacc	ttgatgtgtt	2520
acaatataag	acagcaaact	taattataaa	tgttgtgcat	gtactaactg	ctccgctgat	2580
tcgtttcccc	atcccacttc	ttcttaggcc	ttcctatttc	ctgagacaca	gtaataatac	2640
atacaatgac	ttctaaatgt	tccagtgaac	agaaaaagtag	caggtctctc	aatttaaacc	2700
aaaaatataa	aggaataagt	ttaatgagta	ctatagttaa	gatattgttt	gcttgaccct	2760
acaaaatcct	gtgttgaaat	ttgatcacca	atattggagg	tggggcttga	tgggaagtgt	2820
tagggctcatg	agggttagatt	ccttatgagt	acattaatgc	tctccctggg	gaaatgggtg	2880
agttcgttct	cactctatta	ggctccagga	gagataatta	ttaaaaagag	ccaggaaacat	2940
ccaccttctt	tctcttgcac	atctctcatt	atctgatccc	tgacttgcct	ggctcccaac	3000
atcttcttga	atgagtggag	gaaaccagag	gtcttcacca	gacacagatg	ttgggtgccat	3060
gcctcttgta	taccctgaag	aattgtgagc	caaataaaaa	cctttttctt	ttacaaaata	3120
gacagcctca	gttattcctt	tgtagcaaca	aaaaaaagcct	gggacaggcc	aaaaactaca	3180
ccattgcacc	aaacagttaa	acaagatgtg	agtgcacagg	aaaagttttt	ggaggaaatt	3240
aaaagtgtca	ctccagtgtg	catacaaatg	ataagaacaa	ataaccatta	tcagtgtctga	3300
tatggagaaa	attttagttg	tctggagaga	aaatcaaatt	agctagccag	ctgcagtgat	3360
tcataatctgt	aatcccagta	acttgggagg	ctcaggtggg	agaacggctt	gagccagaaa	3420
gtttgaagtc	caaggctgca	gtgagctatg	attgctccac	tgacttccaa	cctaggtgat	3480
agagcaaaac	taccctgaaa	aaaaaaaaaa	gaaaaagaaa	gaaaaaaaaa	agaaaaaaa	3540
ttaaaccaac	cacaacatca	ccttaggttt	tggcattagc	taaaaactaa	tacatagtaa	3600
agcgttaact	attcaattgc	atgaaacctc	agagaggaga	ggaagatgca	gaaaaaaaga	3660
ctgaagctag	tagaggttga	ctaattgagg	ttacaggaat	aaactgccta	catgatgcaa	3720
aagtccaatg	tgaagcaata	ggaagtcatg	cagaagactt	agctaataa	ctcagtaaat	3780
gtggctacag	taaacaaatg	attttcaatg	tagacctaac	agccttctgt	tggagaaga	3840
tgccatttaa	aactttcata	gctagagaag	agaagtcaat	gcttgtctct	gaagctacaa	3900
aaaaacaggc	gaatctcttg	tagtggctaa	tgacagctgat	gacaaaggta	aagccaatgc	3960
ccatttactt	tttgtaataa	ttatagagga	ctcttaataa	ttatgttaaa	tctactttgc	4020
ctgtgttata	tcaatggaac	aacaaagcct	ggatgatata	acattgggat	atgacatggc	4080
ttattgaata	ttttaagcac	actgttgaga	cctattgtct	aaaaaagagg	attcctttca	4140
aaatattgct	gctcattgac	aattcacatg	gtcaacaaag	ggctctgatt	aagatgtaca	4200
gatattaatg	tttgctgctg	tgctattatt	acatccatct	tacatgccat	ggatcatata	4260
gccttgactt	tcaagtctta	tgtaaagaa	atatttttga	aggctatagc	tcttactaat	4320
ggggaaagta	tattgaaaac	cttttcaaaa	ggatttttca	ttctagattc	cattaagaac	4380
attcatgggt	catgagagga	agtcaagata	ttacacattaa	caagagtttg	gaaaaaattt	4440
gattctaaact	ctcctggatg	attttgaggg	tcatgtgaag	tcatgtgaag	aattaacttg	4500
ggatgggggtg	gtcatgaaaa	aataaataga	attataagtg	ggcctgaagg	tttgtctaaa	4560
ttgctataat	atcatgataa	aactaaaacc	tgtaaaaccg	gtgaggaggt	gctttttaaa	4620
cagttacttt	ttatagatga	acacagaaat	tggttttgtg	agttggaatc	ttctccgagt	4680
gaaaatgtcta	tgaacattgt	tgaatggctt	acaaatgact	tagaatatta	cacaaaatta	4740
gtagataagg	cagcatcaag	gtttgagaga	atggactcaa	attttgaaag	aaattctact	4800
atgggtaaac	tgctgtgaaa	catcatcata	tgctacagag	aaatctttca	tgaaaagatg	4860

```

agtcaattca tgcaacaatc tttgttgtct aattttaaaa attgtccagc tgccctgata 4920
aatcaacagt aatcagcact gaggcaagac cctacaccag aaaaaataaa aataaaaaaac 4980
ctcacttgct gaagactcag cttattatta gcacttttta gccatacttt taactaaggt 5040
atgtgcattc ctttttaaac gtgatgatat tgcacagcta atagcctaca aggtatgggt 5100
aacataactt ttatatgtcc tgggacccaa atttgtgtga atcactttat tgacatattc 5160
cttttattga gatgaactgc aacttatctt gcaatatctc caagatatgt gtgtatggca 5220
tttcaataaa gatgtgaaat tattttatta gtataaaaag caaatttaat tttctttcct 5280
ttgatcatct ttatccttgt tactgtgtat ttatccttta aacattgaat gactccaatt 5340
gtttaaaact gagtctttct taaatgagtc ctaatatcat agtaattaaa atcacctaca 5400
agttggtaat gcaggcagca tgtgaggcac agaaaacaac aaatttataa gacataaatg 5460
catttgcttg gaagctgaga gaaggctcta ttctaatttc tgataacttc aaactgagta 5520
tcttcagtaa aatttattca ctatcaaatt caaggcggtt ggatttatga cctaggaaaa 5580
aacttcaaac attaaaatgt gatgacctta aaaagagggt ctccacacta tgggtgtataa 5640
caccaccaac tttgattaga attttaaaga gaaacaaatt ctcttatgga gtttatcttt 5700
ttatcacttg caaaatatgt ttttgtaaag agatactaata tacttagtta tttgtagtta 5760
gccattcttc tgattaaaaa cctaaaatta aatcttgaaa atgtgttttc cttcaaaaaca 5820
catcatttga gagaaacact aaagtaagtgt tatgattatc atagcatgta catagggtct 5880
tcacaaccca aaaagaatat tgtcatgggt aagaatcagt aaaggaattt ctccataata 5940
aacagtagcc tattaattaa agtaatgata tgcaatacag caagttaaag ggaactgata 6000
ctgggtggat tattgaaaga tataaccttg actatagatt agaaaataca gagatgttat 6060
ttagtgaaaga tatttgtgga ctcatttatc atctgcaatt cacttgcaga ggaaaaaatg 6120
agtaataaat tcatttgcac tttggatttg tgtctttaag ttgtgaaaat acacttaaat 6180
ataaccatct gtcctttgct ccttccttcc ttccctcttt ccttccttcc ttccctcttt 6240
ccatccttcc ctccctccat ccttccttcc ttcccttctt ccttccttcc tttctttctc 6300
tgtccttctc tcttttttcc tttctttctt tttctttctt tattatttca ttaattcccc 6360
cttccatttg acgtctaaaa gccatgttgt tctagaggac ttaaacttat ttttttctta 6420
atagcttact gaaaaattag tgatacaatt ttttatttga attgtatgct aattcattct 6480
gttatttctt ttattgagga agggccacta cattatgtga gactgtggga aaagctgaga 6540
tatggctaata acgaacatat tgggattttg aatttcctca accataccaa cctaactttg 6600
agtttggttg aggattgcac tgtaaacctg ccaaagcttt gcctaaggta ggactattgt 6660
attaaggaat attatgtact ttatgacatg acttgttttc ccttgaaaga ttacaacctt 6720
agttatgaaa ggatgatgtt gaatgtcgct tgtttgcagc tccatattta ttttccatgc 6780
cacaggggct cttataggtg attatatgtc ttttcgggat tatattgaga aagtaggcag 6840
aagaatttca tgattagaat agatttttaa atactagtat tacaatagtt tggataataa 6900
attgaattaa tagggaattg gagccatgaa gatcactaaa aagaatgctc tagcctttct 6960
cacaatcaaa ttgggcttat gaacaaggat atttgtcatg atagtacaga aataagcata 7020
ttttcatgag acatattgga tatattccac aggagtgggt gagtgagaga aaataagtga 7080
tgaaggaaga caaagaataa aagaaaattt caataaatgg aaagttaaag tgtttaatga 7140
tagtgatgac ttttactcaa ataagtgcct agaagtcac ttgtttgtga tttatatgat 7200
gaattctgtg ttgtgactat ccactttgag ctcgtagaaa tgttaggtga ggtttaataa 7260
aagccatttg agaaaaacaa ggtttcaacc tctgtggaca gaaatctaaa tatcgatagt 7320
tatcaggaca aagtagagct catagaaata attttgcagc ctgcagggtt gttttggagt 7380
gaaaataaaa ttgtatacta tattcctaaa tcatcagagg aaaaaattta tagttcaagg 7440
aatgttgaaa gaaacaatat tgagaagtaa aagttagtaa tagttgttat agttttttta 7500
tagtttttga agtatgtctt gagttcactg tcccaaaaag ggctattagc tctagccttg 7560
acctgacaag gttctaggat atttagtcac ggatgttcat aatctacctc ttacgggata 7620
ctttttatto tgatgaacag cctaattgcct aagtgtgcaa tctataccaa gattgttctt 7680
atagggaaact tgtttacact ggaagacacc actgtgtctc ttgtatgacc tatgtcttct 7740
ttatccctac aaaggtaacc acattatagg aaaccctgac aaggccagat gttatatttg 7800
tgttggtcaa gtgagaaaac atgggagaaa ctaaaccaaa cacataaaat aacagaaaca 7860
gtcttctttg accatttcta gagaaaagag ttcagcatcc cttgtaaggc cactaggaag 7920
aagaaaattc tctgggaaaa gcacattcaa ccaatgaatg gagaccaaga aagagagtga 7980
gggatctatg tgccaaaatg ttaactggga tccagggtgt tacctagggt ggtttccaat 8040
ggggaactgt aattggtagg tttaatgcaa gcagcacaaa agtccatgga ggcattctga 8100
gactgaaaga tagtcacttt ggcatactct cacagaatct gatcagtgat tcaagcccaa 8160
gtaggctgta tctagtgtgc ctataggggt gttaccagga ggcagtgtgt aagtaaaaaat 8220
cctgactgaa cacattgagg aaatggaagg aggtggaaga ttttaaacgg tgtcagtgtt 8280
gactaagacc tgcttctggt atggaaaatt caacttatat tttaaatgca tagccagaca 8340
acataaaatt ataagaattt accacaatag ctatggtaac aatactgggt ttacctatta 8400
ctacagagtg aaaaagaaac cctcatttcc cattttatgg aaatataatc aaaatcctat 8460
aaggaagggt tcagagccag taggatttcc agaaaaatta ttggttttat agtaagatgt 8520

```

gtattgatga	atataat	tttattaat	tattaat	actttactta	ccaggaaagt	8580
tataccagaa	aaccaagctc	tcttaagcca	tggcatctgt	atctaaaata	gaaatacaga	8640
aggagagctg	acaat	tcat	ggtaat	catgccattc	taccctttat	8700
tcccacactc	ccagttttac	acacacacac	aaacacacac	acacaaacac	acactcatag	8760
aaataatcat	agaagacata	tttttaaaaa	agtttagatcc	atacagtaat	aatttattag	8820
gtaaaagctt	ttgtgctgat	aattttacaa	gtttaattga	gataat	agggctgtct	8880
tacactaaat	at	at	tttgacatgt	aataattgca	catgtttaag	8940
agaaatgctg	tggtattaca	atacatttaa	atgttggtga	ataattacat	caagataata	9000
aacccatcat	ctaaat	atcatttctt	tgtgggtgata	acattcaaaa	acctcctttc	9060
tggtctatctt	gaaat	atacattact	attaactata	gttaccacaac	aacttaatat	9120
aataacagaa	catattcttc	caaatttaaa	cggtgtatcc	attgatccac	catttctcat	9180
tgccctccct	actatctctt	cagcctctag	taaccacaat	tctactctct	aattatatta	9240
tgaatgcatt	ttttgattcc	acataaag	gataccatgc	tatctctgcc	tggattattt	9300
cagttaacat	tatgcctg	aggttcattc	atgtttctac	aaatgacagg	at	9360
ttttttcca	atatat	aatgaaatgg	atatatataa	acattggaaa	atgtatata	9420
atatatata	ctccagt	atgctattga	gctataaaaa	agttaatata	taatagaaat	9480
aaagcttata	tatatcta	ggaatggata	tatatata	atggaataga	aatatata	9540
tatacatata	aacacacgca	atatacatat	ccatttcat	gcataatata	atatata	9600
agagagagag	agagat	tcaa	gtatata	ccaatggaat	ggacata	9660
atatgtatat	ttttccata	ttttctttat	gtatttcttc	attaatggat	gttaggtt	9720
attcatccct	tggttat	aataatgttg	atgtaa	agaaggacag	atatctctat	9780
gacttcttag	tttatttaaa	tatacaccca	gtaatggaaa	tgctgtataa	tatggtagtt	9840
ctatttctca	tttttgagga	actaccatac	cgtttctctt	actaattgta	ctaattt	9900
tttccctcaa	cagtttataa	aagatcttct	tctctgc	acttctagc	acttgttatt	9960
tttgccctttt	gataatagcc	ataacagggg	tgatgtgata	tctcattgta	gttttgattt	10020
gcatttccct	gatgattagt	gattttgagc	at	tatacttctt	agtcactgat	10080
agtcttcttt	tgagaagtgt	ctattcaggt	cttttgctta	ttttttaatc	aaattagtaa	10140
tttattttta	ttgactgatg	tgacttctat	gtatatttga	gatagtaact	tattgtcaga	10200
ttcatagttt	gcaa	ttcatgttgt	gaattgtctc	ttcacctgt	tgttgtctt	10260
at	cacaagctca	atgctttgat	ataaccatt	tatctacttt	tccttttggt	10320
ggctgtgctt	ctgaagtcct	atccaaaaaa	atccttgctt	agaccaatgt	cacaaatcat	10380
tcctcctaca	gtttcttcta	gtagttgtat	aatgtttggc	cttatattta	actttgta	10440
tcattttttac	ttactttgt	tatggtgagg	gatagaggtc	tagtttcat	ttctgc	10500
ggatatgcag	ttttcctagc	accatttagt	gaagagggtt	cctttttct	attatgtgtt	10560
cttggcacct	ttgtcaaaag	tcagtttagct	gctatattcc	tccatttggt	ttgttataga	10620
ggaacacatg	agactagcaa	at	caa	tatttgaatg	atagttctgc	10680
atactgtaca	agaagcacag	cactgacttc	tgcttggcct	ctggtaagg	tctcaagatg	10740
cttccacttg	tggtagaagg	caaacatgag	ctgggtat	caaagggtctc	atgacaagag	10800
aggaacacat	aaagaggga	tgtaggggag	tgccagggtt	tgtaaaacaa	ctagctcttc	10860
tggaactaa	tagagtaaaa	attgcctcc	caggcagggg	attaatctat	tcatgaggga	10920
tctgcttcca	tgacaaaggc	acattctgtt	agattctacc	cccaatattg	gggatcaaat	10980
tttaacatga	agtgtggagg	gctcaaatat	ccatactatg	gcagcagtaa	atgcataaat	11040
ttattttgtg	gatctctatt	ctatatagta	ttggtgtatg	tatctgtttt	catgccactg	11100
ccatactgtt	ttggtgatga	tatctatgct	atatatgtgt	gtgtgtatat	atatattata	11160
tatatgtata	tatgtgtata	ttatatatat	gtatatatgt	gtatattata	tatatataat	11220
actttaagtt	ttatatatat	ataaaatact	ttaagttcaa	gggtacatgt	gcaggatgtg	11280
caggtcagtt	acataggtat	acatgtgcc	ttttgggttg	ctgcatgcat	caactcatca	11340
ttacatttagg	tatttctcct	aatgctatcc	ctccaccagc	cacccaaccc	ccaacaggcc	11400
aggtgtgtga	tggtcccg	cctgtgtcca	tggttctca	ttgttcaact	cctacctaaa	11460
agtgagaaca	tgagtggtt	gatttctat	ccttggtgata	gtttgctgag	aatgactgtt	11520
ttcagcttca	tccatgtccc	tcaaaaggac	atgaactcat	ccttattttat	ggctgcatag	11580
tattccatgg	tgtatatgtg	ctacgttttc	ttaatccagt	ctatcactgt	tggacatttg	11640
ggttggttcc	aagtccttg	tattgtgaat	agtgtacaa	taaccat	tgtgcatgtg	11700
tctttatagc	aacatgattt	actatccttt	gtgtacatac	ccagtaatgg	gataactggg	11760
tcaaatggta	tttctagttc	tagatccttg	aggaatcccc	acactgtcct	ccacaatgg	11820
tgaactaatt	tacattccca	ccaacaggtg	aaaaacgttc	ctatttccc	acatcctctc	11880
cagtatctgt	tgtttctga	ctttttaatg	atggccattc	taactcacat	gagatgggtat	11940
ctcattgtgg	tttttggtt	catttctctg	atgaccagtg	atgatgagca	tttttcatg	12000
tgtcttttgg	ctgcataaat	gtcttctttt	gacaagtgct	tggtcatatc	ctttgcccac	12060
ttttcaatgg	agttgttgt	tttttctctg	taaatttgtt	taagttcatt	gtagattctg	12120
gatattagcc	ctttgtcaga	tggttagatt	gcaaaaattt	tctccattc	tgtaggttgc	12180

ctgttcaccc	tgatggtagt	ttcttttgc	gtgcagaagc	tcttttagctt	aattagatcc	12240
catttgtcaa	tttcggcctt	tggtgccatt	gcttttggtg	tttttagtcat	gaaacccttg	12300
cccaggccta	agtcctcagt	ggtatagcct	aggttttctt	ctaggatttt	tatggtttca	12360
ggtctaacat	tttaagtctt	aatccatctt	aaattaat	ttgtataaga	tgtaagaagg	12420
gatccgtttc	aactttctac	atatggctag	cgtgttttcc	caacaccatt	tattaaatag	12480
ggaatccctt	ctccatttct	tgattttgtc	atattttgtca	aacatcacat	ggttagagat	12540
gtgtagtggt	atcactgagg	cctcttttct	gactccattg	atctatata	ctgttttgat	12600
accaatacca	tgttggtttc	gttactgcaa	ccttgtaatg	caatttgaca	ttcaggacca	12660
tgatgcctcc	agtctctttt	tttttttcta	aataattttt	ttgtcaatgt	aagctcattt	12720
tcgcttcttt	ctgatccata	aagtattttt	ttcccat	gtggagaacg	ccgcnnnnnn	12780
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnggcac	12840
cctcggtgcg	atatatatata	atatatatata	atatacctct	atatatatata	acatacatag	12900
atacatacac	acctccttgt	ctgggtgtgg	atcagggtaa	tgctagcctc	acaagatgat	12960
actgaagtgt	ttttgccttt	ttgacttttt	gatggtttgg	aagagtgaga	aaaagtgtta	13020
tttaattatc	tttaaaat	gttgaatttc	atagtgaaga	ccttagctca	ctggcctttt	13080
taatgagaac	tttattactg	atttaaactt	cttcttcatt	atttatttct	gccttgtttt	13140
tatttcttca	taatccagtc	ctattttatg	tgtccactaa	attgtttatt	ttcctagaat	13200
ttttccattt	attggcatat	gcatgtccat	agaagccttt	tatagtcctt	ttcatttcta	13260
gtgtcatttt	tttccctttt	tttaagaatc	cttaagattt	tagagatgaa	atgtcacttt	13320
gttacgcata	ctggagtgcg	gtgacattat	tatagctcac	tgaaacccaa	actcctgagt	13380
ttaagcaatc	cttctacctc	aaaattccaa	aattcctgag	tagctgagac	aggcatacac	13440
catcaagact	ggctaattta	tttcaaattt	tgtagagatg	ggttcttact	aagctattct	13500
caatctttgg	gcttcaagtg	attcttcagc	ctctgtctct	gaaaatgctg	ggtttataga	13560
tatgagcctc	tatgcctgat	ttgctttgtc	tctttgtaat	ctcccatttt	atttgtgtct	13620
tttctggttt	gtttcatttt	gttatgtttt	cagttacctt	gctaaagctt	tgctgatttt	13680
atctcttcaa	acaactaact	caatattttg	ctgattttcc	atatagtatt	ttatttctat	13740
ttcattttatt	tctgctctaa	tctttgttaa	atatcttggt	ttcctaataa	ttttgagttt	13800
ccttgttctt	gttttcta	tccttgogat	gttatcataa	attgtttatt	tgatatcttt	13860
ctactttttt	gatgtgtgtg	ttcgttggtg	tagactttcc	tctttattat	tctgatttct	13920
tcctcaattc	tctaataatta	tgattgcatt	attttccaag	tttcttttgt	ttttttattt	13980
atagtttatg	tgattcctga	acttgtcaaa	gagattattg	tgaatttgat	gtcggatatt	14040
taagcatttt	caaaactttt	ggtgcattat	tgaattttta	ttggtttatt	ttagagatgt	14100
catacttccc	agtttttttt	taacaatact	tgctctttat	attgatgtct	acatatttta	14160
aaagataacc	acctgattca	gctttttaag	gtgatatgca	gtggtgttaa	gtgtgtactg	14220
cttaaatcca	gagctgaatc	actgcctga	ggattctttc	tgttctgagg	agagctgtga	14280
gttaatagca	gaacctaaat	agtgcagtag	agctaaatct	cttccatgct	gttggtttcc	14340
tgtctgggga	agacttatca	tgaccatgaa	aacataatgc	tgtgccagaa	cttaaaccca	14400
aacctgtagt	aatttctgag	ttgaggaagg	cttaagaaat	aactggaact	tagttactaa	14460
cctgatagt	gtttctgagt	cagagaaatg	ctctgcata	tcacctggga	tatttgtaaa	14520
atctaaccac	agattctagc	cttccccttg	gatttgtgct	cctgtactac	tgtagtgtctg	14580
gctagtcct	catcagtga	ttccctgctg	ataggaccac	aaagcatctg	ccaagatctg	14640
tttgccattt	gctgtgatta	gtgcttctgc	tctttgcttc	caattcaact	cagggtgttc	14700
agccctctg	acactcctaa	tacctcctgt	gggatggaac	atagaaggct	tctcacaatg	14760
attcacacac	tgatatggag	attgaatgtc	cagttgcaac	tattttcttc	cacctgtgta	14820
attgcaggta	cagggaagtt	ttctgtgact	gatgctattt	tggtttggag	aatggggtga	14880
tgtggcacaa	tgatctttct	tctttctggt	catggatttt	tttaattcca	tgaaccata	14940
agatttttca	cttttcttct	gagctctggt	gctttcagag	tggtattttt	atattcgaat	15000
agttgctagt	tgtactttta	aaagcgattg	atgctggagg	tcttctattc	caccatctcg	15060
ctgatgtcag	tcctcaaata	ataattttat	atttttagcaa	attatttttg	ttttaggatt	15120
ttgtgtctac	gtgacacaga	catgaaaaga	gatgtactca	ttactgaaac	tttttgcata	15180
ctgttttgg	tgtgcgcctt	ttctagtatg	aatgattaca	tatttaagcc	acatgtttta	15240
tacatagact	gtccttttaa	gagactagat	agttctgtgt	gtcagcatat	agggacagaa	15300
tataactaca	cattaataat	ttctcaagta	tttatttttag	aagtgtgaag	aacctttatt	15360
tttaattttg	ttatattatg	cctctgtaat	gcagataaat	ttttatcttc	aggaaatgga	15420
aaattttgtc	cagagttcag	gggaagatgg	tattgtgggtg	ttttctctgg	ggtcactgtt	15480
tcaaaatggt	acagaagaaa	aggctaatat	cattgcttca	gcccttgccc	agatcccaca	15540
gaaggtcagt	aaaacctcca	atcctgataa	gcagctattc	acataatgaa	acagtatggt	15600
tttatttggg	tcttgaatct	cattttccac	ttagcataac	aggtaccaa	atttgcaaaa	15660
cattatagta	gtgtacatgg	gcataactga	tcatttgcct	actgagtctt	gctgttactg	15720
gaaacaactt	tcttgattgt	catttgttta	taataaaaata	gatataataa	ataaagctct	15780
accttatatt	ttaggatttg	aaatctaaaa	gcgtgtgcc	atgattccaa	aaaaaaattc	15840

tgacatctat	tatttcaaag	gaccagaaaa	aggaaaactg	atataaaaaa	aaaaagaaga	15900
atcaatctca	agaatatctt	ctcatatttg	tgtgtataaa	aactgtattc	agggtagttt	15960
tgcttagaaa	taaaagctca	gattaatgta	gtctttctaa	ataattagaa	gtttcaaaag	16020
taaaatgtca	attacaatta	tagtatagta	acaattattt	aagtaatgta	attattttatg	16080
atactccact	aattttaact	ttattattac	tgtaattcta	gaatttcaca	ctttagatag	16140
tgctatatat	aaactatcca	aaagatattt	cattttatat	ttagctaaaa	tacttcaaac	16200
tcaataaaag	caagcatact	aattaggaat	ttgaaatatt	gtaatttcaa	ttatgaaatt	16260
atctgttaa	tagtttgaaa	catctatgcc	gttctttgtt	ttcaaagtga	taaaatttgt	16320
ataggtgtcc	aacaaagaaa	aattgtgtaa	aaaaaaggta	caatctcaaa	gaaaatttat	16380
cattgaacag	tggaaacata	gtaattttct	agctcattct	tcttcaataa	aacaattaaa	16440
tataagaaga	aagaggccag	gaaggaaata	gagaagaaaa	gacacccgat	tatccaaaag	16500
acacacataa	ttgaaagcaa	atttttatct	gcagggaact	gtaaatttga	tggtagaatg	16560
agattggctc	catgagttaa	aatgacacac	agatcaggta	cttataaaat	ttttaattct	16620
tataataaaa	tagatttagcc	actgctgaat	tattttttta	aatattcact	ggtatttctca	16680
ttctcaataa	tttttaattg	gtaataaaat	aataatagca	tacctaatag	gcaactggta	16740
cacattattt	taaaagatct	ttgtaaaacg	tcctactata	tctttcagtc	tttacgcggt	16800
agctctacac	accctgtct	caaccatcac	ctgaagtaca	atgagtttat	aattttatac	16860
tatatctaca	tccttagaat	gctaatatcc	tgtggttcac	tctgtgaaat	acatgtgttt	16920
cttcgcgtag	tgttatggag	gtacaaagga	aaaaaaccat	ccacattagg	agccaatact	16980
cggnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	17040
nnnaaaaaaa	aagacccaat	cccaaagaaa	atttatcata	gaacaatgga	acataggtaa	17100
ttctctagct	cattcgtctt	caataaaaaca	aataaatata	agaagacaaa	ggtcaggaag	17160
gaaatagaga	agaaagata	accgattatc	caaaatcaca	cacaaaattg	aaagcaaatt	17220
ttatctgtgg	ggaactgtaa	atttgatggt	agaaccagaa	tagttccatg	atttgaaatg	17280
acacagagat	catgtactta	taaaatattt	tattcttata	agaaaattga	gtagccagtg	17340
ctgaattact	ttttaatgat	tcaactgat	tctcactatc	agatatttta	attgatatta	17400
aaataataat	agtatactta	atagtcaact	ggtacacatt	atttgaaagg	acttttgtaa	17460
aaagtccctac	tatgtctttt	actgtttaca	cagtacctct	acataccctt	gtctcaacca	17520
acacctgaag	tacaatgagt	ttataattta	taactatatc	tacatcctta	gagtgtcaat	17580
atcctgtggt	tcaatctgtg	aaatacatgt	gtttcttcca	taggtgttat	agagatacaa	17640
tggaaaaaaa	accatccaca	ttaggaacca	atactcggct	gtatgatggg	ataccacaga	17700
atgatcttct	tggttaggtct	atgagaaagt	aaaaatatga	actagacgag	gaaaaaatga	17760
ataaatgtta	aacagcaagc	aaattcagca	aagatctaaa	attataaaac	tttattttac	17820
ttactctttt	gaagcagata	taattaaagg	attgactaaa	attgtataga	ttcacacttt	17880
ctattgttaa	ggtgagagtg	acaggaaatt	cagaaggaat	taatgcctat	ttttctggag	17940
atagaaatga	totttagtag	caatgctcca	tgtgctcacc	ttctaagaaa	agtgtcttac	18000
gcttcagtg	gttatctcgt	aattcccact	tgtagttttt	aaataatttt	aaaagtttag	18060
aataaaatat	ctcatccaat	ctcatccaat	ttacatacta	ggtcatccca	aaaccaaagc	18120
ttttatcact	catggtggaa	tgaatgggat	ctatgaagct	atttaccatg	gggtccctat	18180
ggtgggagtt	cccatatttg	gtgatcagct	tgataacata	gctcacatga	aggccaaagg	18240
agcagctgta	gaaataaact	tcaaaactat	gacaagcgaa	gatttactga	gggctttgag	18300
aacagtcatt	accgattcct	cgtaagtact	actgcttgta	cagactgatc	taacattgac	18360
tatgtttatc	attataccag	aaaatgttaa	atatcatcct	ggtagacatg	ttgagggatt	18420
ttactccaca	atattgagtc	attcatcacc	ttgttactgg	aatagttgtg	gaaattgtag	18480
ttcatagagt	gtcaaacttt	cttcatggaa	atattagggt	taagttaaca	actggcttac	18540
taagctttta	ttcacatctt	aatttttacc	cattttgtta	agaatatact	ctttcagttc	18600
ctccactata	tctgtttaat	actatgtaac	caacaatatt	catgtcacaa	ccagaatcaa	18660
tcttttactg	aacatgttct	tggtttgcat	aacatatact	acggtttatc	tacgtgtctt	18720
ttatgaaaac	aaaactacaa	ctttctaaag	tctatgtgtg	tttttccctt	ccagttataa	18780
agagaatgct	atgagattat	caagaattca	ccatgatcaa	cctgtaaagc	ccctagatcg	18840
agcagctctc	tggtatcgagt	ttgtcatgcy	cccaaaggga	gccaaagcacc	tgcgatcagc	18900
tgcccatgac	ctcacctggt	tccagcacta	ctctatagat	gtgattgggt	tcctgctgac	18960
ctgtgtggca	actgctatat	tcttgttcac	aaaatgtttt	ttattttcct	gtcaaaaatt	19020
taataaaaact	agaaagatag	aaaagaggga	atagatcttt	caaatttcaa	gaaagacctg	19080
atggggtaat	cctgttaatt	ccagccacat	agaatttggt	gaaaaccttg	ctattttcat	19140
attatctatt	ctgttatatt	atcttagcta	tatagcctag	aattccacga	tcagtagggt	19200
gtgagtatat	ctcattcttt	cgttgtatatt	tcctagggtg	ctttactctc	ttctctcact	19260
ttgtgacaca	aggacatgaa	tacatctaaa	ttttcctatt	tctgatatga	ctgttttgat	19320
gatgtcatta	cttctataac	cttaagtgat	agggtgacat	gcaatatgat	tattcctggt	19380
gtgcgcccaa	acacatggat	ataaagaggt	aaaaaactta	aaattcacaa	aattcagtaa	19440
accacacaaa	tcaggtaagt	gttctatgag	attagctggc	tatgagaac	ataatgatgt	19500

```

ttctttttca atttaaataa gcccttctac atagccagca tcagtgtatc cagaaaataa 19560
attgctaata atgatgacat ggcattatgc ttagaaaagt ttgctgtatt tccatagacc 19620
tcatctagat gtcattggcct acatttctgc catcactcaa ccaatacttt tttctgtttt 19680
cttgatgata aaaagacctt tctcatgatt gccatcaaat aacaaaagaa actatttttt 19740
ttctcacata gagaacatgt cagtaagata ttcaagggtga acagatattt ttgggattag 19800
taactatttg aaatatgtgg tgataattac tgagtttata aaatttattt gatagtacac 19860
ttaaagaaga ttatatgttt tattctttta aaatgatgaa tactcataat tcttatctct 19920
ataatcaaaa gtataattta ctgtagaaaa ataaagagat gcttgttctg aaagtaagat 19980
cagtgaactg cttttcagtc tcaatctttg agaattgtaa attcatcaaa taattgctta 20040
catagtaaaa atttaaggta ttagaaaacc tgcataacaa atagtattat atattaaata 20100
ttttgatatg taaagctcta cacaaagcta aatatagtgt aataatgttt acactagtaa 20160
gcaaatatgt taatcttctc atttttttac tgtcatataa tcttagtgat atgcctatta 20220
atagttttta ataaataaat tggcttatct ggctttttga aaattttgaa attcttacag 20280
atgttgatta ggtatatcta caaattaatt tcaattttta aatgatgata taaaaataaa 20340
tataagtatt tttcttgtgt atgtatacaa taaatataaa taaaattgtt tactgttttg 20400
aaagtttctt aagtttttac actgatatgt tttttgactt ttacaatatt attataatct 20460
aggaaaagct gattatatct gttttaagcc tcatcttttc tctgtaatta aacacagtaa 20520
tttattaaca tgctgtgaca ggtgggaagc cattttetgga gttgagcctg ctgacactct 20580
ggagcttttt aggttgagac ttcatgtgat gtgggactct ctgcctctcg atagctgttg 20640
ctcataagac tctccttcat caatctggca ttgaattttg cgatcagttg caatcagaat 20700
ccaattggcc ttgccgtttt agtatgttct atcttaacca gcaatttcta accaggagcc 20760
tgcccaggtt tgttctgtct tccctgtaag aagctcccag cataaatatt ctaaaatttta 20820
cactactaat ctattaacca acctttggac catgttctact ttaggttgag catagtgtga 20880
tgagatgcaa attaaattac aatcctatag gtgtgtgtta taaattttta agtgtataaa 20940
ttaaataaca cattctaagt atccaacaaa ggtcaaaaaa atgatataaa gtcaccaaac 21000

```

<210> 4

<211> 449

<212> PRT

<213> Human

<400> 4

```

Met Pro Gln Asp Arg Thr Glu Glu Asn Glu Ile Phe Val Asp Leu Ala
 1          5          10          15
Leu Asn Val Leu Pro Gly Leu Ser Thr Trp Gln Ser Val Ile Lys Leu
      20          25          30
Asn Asp Phe Phe Val Glu Ile Arg Gly Thr Leu Lys Met Met Cys Glu
      35          40          45
Ser Phe Ile Tyr Asn Gln Thr Leu Met Lys Lys Leu Gln Glu Thr Asn
      50          55          60
Tyr Asp Val Met Leu Ile Asp Pro Val Ile Pro Cys Gly Asp Leu Met
      65          70          75          80
Ala Glu Leu Leu Ala Val Pro Phe Val Leu Thr Leu Arg Ile Ser Val
      85          90          95
Gly Gly Asn Met Glu Arg Ser Cys Gly Lys Leu Pro Ala Pro Leu Ser
      100          105          110
Tyr Val Pro Val Pro Met Thr Gly Leu Thr Asp Arg Met Thr Phe Leu
      115          120          125
Glu Arg Val Lys Asn Ser Met Leu Ser Val Leu Phe His Phe Trp Ile
      130          135          140
Gln Asp Tyr Asp Tyr His Phe Trp Glu Glu Phe Tyr Ser Lys Ala Leu
      145          150          155          160
Gly Arg Pro Thr Thr Leu Cys Glu Thr Val Gly Lys Ala Glu Ile Trp
      165          170          175
Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Gln Pro Tyr Gln Pro
      180          185          190
Asn Phe Glu Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Ala Leu
      195          200          205
Pro Lys Glu Met Glu Asn Phe Val Gln Ser Ser Gly Glu Asp Gly Ile
      210          215          220

```


Val Val Phe Ser Leu Gly Ser Leu Phe Gln Asn Val Thr Glu Glu Lys
 225 230 235 240
 Ala Asn Ile Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val Leu
 245 250 255
 Trp Arg Tyr Lys Gly Lys Lys Pro Ser Thr Leu Gly Ala Asn Thr Arg
 260 265 270
 Leu Tyr Asp Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr
 275 280 285
 Lys Ala Phe Ile Thr His Gly Met Asn Gly Ile Tyr Glu Ala Ile
 290 295 300
 Tyr His Gly Val Pro Met Val Gly Val Pro Ile Phe Gly Asp Gln Leu
 305 310 315 320
 Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Glu Ile Asn
 325 330 335
 Phe Lys Thr Met Thr Ser Glu Asp Leu Leu Arg Ala Leu Arg Thr Val
 340 345 350
 Ile Thr Asp Ser Ser Tyr Lys Glu Asn Ala Met Arg Leu Ser Arg Ile
 355 360 365
 His His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile
 370 375 380
 Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Ser Ala Ala
 385 390 395 400
 His Asp Leu Thr Trp Phe Gln His Tyr Ser Ile Asp Val Ile Gly Phe
 405 410 415
 Leu Leu Ala Cys Val Ala Thr Ala Ile Phe Leu Phe Thr Lys Cys Phe
 420 425 430
 Leu Phe Ser Cys Gln Lys Phe Asn Lys Thr Arg Lys Ile Glu Lys Arg
 435 440 445
 Glu

<210> 5
 <211> 530
 <212> PRT
 <213> Human

<400> 5
 Met Ala Pro Gly Lys Leu Ala Ser Ala Val Leu Leu Leu Leu Leu Cys
 1 5 10 15
 Cys Ala Gly Ser Gly Phe Cys Gly Lys Val Leu Val Trp Pro Cys Glu
 20 25 30
 Met Ser His Trp Leu Asn Leu Lys Thr Leu Leu Glu Glu Leu Val Lys
 35 40 45
 Arg Gly His Glu Val Thr Val Leu Thr Leu Ser Asn Asn Leu Phe Ile
 50 55 60
 Asp Tyr Asn Arg His Pro Ala Phe Asn Phe Glu Val Ile Pro Val Pro
 65 70 75 80
 Thr Asp Lys Asn Met Ser Glu Asn Ile Leu Asn Glu Phe Ile Glu Leu
 85 90 95
 Ala Val Asn Val Met Pro Thr Met Pro Leu Trp Gln Ser Gly Lys Leu
 100 105 110
 Leu Gln Gln Phe Phe Val Gln Ile Thr Glu Asp Leu Gly Leu Asn Cys
 115 120 125
 Arg Asn Thr Val Tyr Asn Gln Ser Leu Met Lys Lys Leu Arg Asp Ser
 130 135 140
 Lys Tyr Asp Val Leu Val Thr Asp Pro Val Ile Pro Cys Gly Glu Leu
 145 150 155 160
 Val Ala Glu Met Leu Gly Val Pro Phe Val Asn Met Leu Lys Phe Ser
 165 170 175
 Met Gly His Thr Ile Glu Lys Tyr Cys Gly Gln Leu Pro Ala Pro Pro

				180					185				190			
Ser	Tyr	Val	Pro	Val	Pro	Leu	Gly	Gly	Leu	Thr	Thr	Arg	Met	Thr	Phe	
		195					200					205				
Met	Glu	Arg	Val	Lys	Asn	Met	Val	Phe	Ser	Val	Leu	Phe	Asp	Phe	Trp	
	210					215					220					
Ile	Gln	Gln	Tyr	Asp	Tyr	Lys	Phe	Trp	Asp	Gln	Phe	Tyr	Ser	Glu	Ala	
225					230					235					240	
Leu	Gly	Arg	Pro	Thr	Thr	Leu	Cys	Glu	Ile	Met	Gly	Lys	Ala	Glu	Ile	
				245					250					255		
Trp	Leu	Ile	Arg	Thr	Tyr	Trp	Asp	Phe	Glu	Phe	Pro	Arg	Pro	Tyr	Leu	
			260					265					270			
Pro	Asn	Phe	Glu	Phe	Val	Gly	Gly	Leu	His	Cys	Lys	Pro	Ala	Lys	Pro	
		275					280					285				
Leu	Pro	Lys	Glu	Met	Glu	Glu	Phe	Val	Gln	Ser	Ser	Gly	Glu	Asp	Gly	
	290					295					300					
Val	Val	Val	Phe	Ser	Leu	Gly	Ser	Met	Val	Lys	Asn	Leu	Thr	Glu	Glu	
305					310					315					320	
Lys	Ala	Asn	Leu	Ile	Ala	Ser	Ala	Leu	Ala	Gln	Ile	Pro	Gln	Lys	Val	
				325					330					335		
Leu	Trp	Arg	Tyr	Lys	Gly	Lys	Lys	Pro	Ala	Thr	Leu	Gly	Pro	Asn	Thr	
			340					345					350			
Arg	Leu	Phe	Asp	Trp	Ile	Pro	Gln	Asn	Asp	Leu	Leu	Gly	His	Pro	Lys	
		355					360					365				
Thr	Lys	Ala	Phe	Ile	Thr	His	Gly	Gly	Ser	Asn	Gly	Ile	Tyr	Glu	Ala	
	370					375					380					
Ile	Tyr	His	Gly	Val	Pro	Met	Val	Gly	Met	Pro	Ile	Phe	Ser	Asp	Gln	
385					390					395					400	
Pro	Asp	Asn	Leu	Ala	Gly	Met	Lys	Ala	Lys	Gly	Ala	Ala	Val	Glu	Val	
				405					410				415			
Asn	Met	Asn	Thr	Met	Thr	Ser	Ala	Asp	Leu	Leu	Gly	Ala	Leu	Arg	Thr	
			420					425					430			
Val	Ile	Asn	Asp	Pro	Thr	Tyr	Lys	Glu	Asn	Ala	Met	Lys	Leu	Ser	Arg	
		435					440					445				
Ile	His	His	Asp	Gln	Pro	Val	Lys	Pro	Leu	Asp	Arg	Ala	Ala	Phe	Trp	
	450					455					460					
Val	Glu	Phe	Val	Met	His	His	Lys	Gly	Ala	Lys	His	Leu	Arg	Val	Ala	
465					470					475					480	
Ala	His	Asp	Leu	Ser	Trp	Phe	Gln	Tyr	His	Ser	Leu	Asp	Val	Ile	Gly	
				485					490					495		
Phe	Leu	Leu	Ala	Cys	Val	Ala	Ser	Ala	Ile	Leu	Leu	Val	Thr	Lys	Cys	
			500					505					510			
Cys	Leu	Phe	Ser	Phe	Gln	Asn	Phe	Ile	Lys	Ile	Gly	Lys	Arg	Ile	Lys	
		515					5									